Skip to main content
Journal of Virology logoLink to Journal of Virology
. 2026 Apr 30;100(5):e00175-26. doi: 10.1128/jvi.00175-26

Is the molecular microenvironment of the latent HIV reservoir predictable using deep learning approaches?

Heng-Chang Chen 1,✉
Editor: Herman W Favoreel2
PMCID: PMC13185613  PMID: 42059621

ABSTRACT

Although current antiretroviral therapy effectively suppresses viral replication in infected individuals, infections remain incurable. One of the main reasons for this is the uncertainty of the molecular microenvironment of the latent HIV reservoir. If this microenvironment can be precisely targeted, the effectiveness of current antiretroviral therapy can be leveraged. To better depict the potent microenvironments of the latent HIV reservoir, it is crucial to first understand the mechanisms that make some viruses transcriptionally active and others silent in the first place. It is currently feasible to predict gene activity from DNA sequence, coupled with epigenetics, using deep learning approaches. Substantial progress has been made in creating multidimensional data sets related to the HIV latent reservoir. The implementation of deep learning to mine potent attributes, enabling the characterization and prediction of the microenvironment of the latent HIV reservoir, is thus imperative. This minireview discusses potent features that can be integrated into deep learning methodologies to predict the likelihood of the potential microenvironment from different tiered levels of the latent HIV reservoir organization, and proposes the principal workflow to tackle this question using deep learning approaches.

KEYWORDS: human immunodeficiency virus, molecular microenvironment of the latent HIV reservoir, HIV latent reservoir, deep learning, HIV integration sites, HIV transcription

THE HETEROGENEOUS NATURE OF THE LATENT HIV RESERVOIR: THE PRESENCE OF THE MOLECULAR MICROENVIRONMENTS

The heterogeneous nature of the human immunodeficiency virus (HIV) reservoir can be considered from different perspectives, including distinct reservoir cell types and specific anatomical sanctuaries (1–3), the genome integrity of a provirus (intact versus defective provirus), a bias of HIV integration sites (ISs) associated with its transcription and reactivation, and replication fitness. Although each of these proposed mechanisms can already reflect aspects of the presence of the molecular microenvironments (MMEs) in the latent HIV reservoir (hereinafter, latent MMEs), it is presently impossible to precisely target latent MMEs, rendering the ineffectiveness of current antiviral therapy (ART) and functional cures. Advanced computational approaches that enable not only mining of the masked features hidden in an intricate data set but also concatenating information retrieved from different “omics” readouts related to latent MMEs, subsequently strengthening the biological interpretation of multigenomic outputs, hold paramount importance.

At present, it remains challenging to precisely define and measure latent MMEs, in great part due to the lack of standard methods to access them. For this reason, in this minireview, I attempt to discuss potential features associated with different tiered levels of the MME organization, including HIV IS (Section I), reservoir cellular states in the regulation of HIV transcription (Section II), the integrity of the HIV genome (Section III), and insert-specific HIV transcription and latency reversal (Section IV). Furthermore, I offer my perspectives regarding the rationale of the prediction of latent MMEs using deep learning (DL) approaches (Section V). Lastly, I propose a theoretical workflow, describing critical steps required to perform this task. Current limitations of DL models when used for prediction and my perspectives on how to enhance the explainability of prediction results on latent MMEs based on small-sized HIV cohorts are also provided. To facilitate reading for experimental virologists, I offer a glossary related to DL modeling (which includes all terms written in italics) at the end of this article.

Section I—potential features related to HIV IS

HIV DNA integration into the host genome is one of the characteristics in the life cycle and is critical for a persistent infection in reservoir cells. The selection of an HIV IS is, by nature, not a random process throughout a linear genome and has been investigated for a long time (4–6). At a genomic level, HIV ISs are preferentially present in actively transcribed genes when cell lines are infected with HIV in vitro without the selection for a latent phenotype (4, 7). Other preferences of HIV IS observed in the inducible J-Lat cellular clones include alphoid repeats in the centromere, gene deserts, and highly expressed genes compared to the constitutively expressed clones (5).

At the level of the 3D genome organization, a bias of HIV IS was observed to correspond to loci in physical proximity to the nuclear pores (8) and active chromatin regions (A1 and A2 compartments) associated with super-enhancers overlain with chromatic immunoprecipitation sequencing (ChIP-seq) signals of the acetylation of lysine 27 on histone H3 (H3K27ac) and trimethylation of lysine 36 on histone H3 (H3K36me3) in a 3D genome (9). In addition, topological signatures, including topologically associating domain boundaries and CCCTC-binding factor (CTCF) (2) and R-loops (DNA:RNA hybrids) (10), also coordinate with HIV IS. HIV integration can be directed by RNA splicing helicase Aquarius—a HIV integrase and LEDGF/p75 binding partner—into R-loop regions positioned in intronic sequences of prevalently transcriptionally active genes, whereas its depletion impairs severely overall integration and retards the remaining integrations out of R-loops and toward heterochromatin-enriched regions (10). Given that R-loops are critical for gene expression (both sense and antisense transcripts [ASTs]) (11, 12), a further investigation of R-loop-dependent mechanisms in terms of HIV sense and antisense transcript initiation and RNA polymerase II pausing on both HIV long terminal repeats (LTRs) is imperative to gain more insights into the mechanism by which HIV ISs dictate its insert-specific transcription (see Section IV). It is important to note that although a similar spatial pattern of HIV IS bias in microglia cells—HIV brain reservoir cells—was observed, the discrepancy exists (2). These findings may suggest that cell-type-specific features should be specified for classification performance in the future, even though it currently remains arduous to achieve substantial accuracy of prediction using DL models in the cell-type-specific context (13).

Section II—potential features related to reservoir cellular states in the regulation of HIV transcription

HIV latency is largely accepted as a consequence of viral tropism for activated CD4+ T cells, which can transition to a resting memory state that is non-permissive for replication (14), indicating that, to some degree, provirus latency resulting from HIV transcription can be controlled by the host-cell activation state since relaxation of activated lymphocytes to a resting-memory state (15, 16). This transition allows integration of the proviral genome in a host cell lacking favorable conditions for optimal viral gene expression, thereby escaping rapid destruction of the infected T cell (17, 18). Latent HIV proviruses can persist in resting memory CD4+ T cells, known as latent reservoirs, with an estimated half-life of 44 months (17–19); treatment is thus lifelong. Although it is still debated regarding the role of naïve T cells in HIV persistence, memory T-cell subsets, including central memory (TCM), effector memory cells (TEM), and transitional memory (TTM), which serve as the main reservoir cells harboring latent infections (20–22), are definite. A recent study observed the inducible reservoir shifts toward a more differentiated T-cell compartment over time after increased time on ART, based on the acute and chronic cohort, suggesting the dynamics of the composition of reservoir cells alongside HIV infection on ART (23). In addition, it is worth noting that a resting-memory state of the reservoir cells has been reported to be correlated with increased epigenetic silencing of the HIV promoter and increased cytoplasmic sequestration of transcription factors that activate HIV transcription (24, 25). The influence of the epigenetic regulation on HIV transcription will be detailed in Section IV.

It is, however, important to stress that, in physiological infection conditions, the latent HIV reservoir can be established early during the acute phase of the infection, possibly before the virus appears in the systemic circulation (23, 26), resonating with a theory that suggests that HIV has evolved a mechanism for rapid establishment of latent infection to facilitate transmission across mucosal barriers (27, 28). Latency was therefore proposed to serve as a “bet-hedging strategy” that allows some infected cells to survive long enough to transit the mucosa. Another more recent study identified a subset of latent cells associated with distinct features from a pool of infected cells with latent infections (29). Remarkably, HIV ISs in this subset of latent cells were prone to be in non-genic regions and in proximity to zinc-finger genes and heterochromatin regions (29). Such biases of integration resemble the features used for the characterization of the reservoir harboring intact proviruses in the status of deep latency in elite controllers (30) or individuals with HIV under prolonged ART, resulting from host immune selection (31) (see Section III). Nevertheless, a continuation of interrogation of potential phenotypic signatures, which tag unique populations of the reservoir cells, such as memory T-cell subsets, a tiny fraction of CD4+ T cells that express CD32a and harbor replication-competent proviruses (32), reservoir cells harboring genome-intact proviruses, and the large HIV-infected clonal population (33), spontaneously active HIV reservoirs (34) (see Section III), reservoir cells harboring proviruses at a deeper level of latency (i.e., elite controllers; see Section III), and a subset of latent cells (29) mentioned above will enrich the complexity of features associated with distinct latent MMEs at a cellular level.

Section III—potential features related to the integrity of the HIV genome

After HIV DNA integration, only 2%–10% of the proviruses remain genetically intact (35–37); others that are genetically defective harbor large deletions, sequence inversions, hypermutations, and defective splice donor and acceptor sites that prevent viral replication (36, 37). At present, reservoir cells harboring intact proviruses are believed to serve as the main sources of viral rebound. Although the role of defective proviruses remains elusive, the study has shown the involvement of defective proviruses in HIV-specific immunity and innate sensing, rather than simply viral genome ‘‘junk” (38). A recent study pointed out the presence of spontaneously active HIV reservoirs, which are dominated by defective proviruses and anticipate HIV-specific immunity in a majority of ART-suppressed people living with HIV (PLWH) (34). A series of studies, based on longitudinal cohort studies of long-term ART-treated individuals and elite controllers—a subset of HIV-infected individuals distinguished by their ability to maintain a state of apparently durable control of HIV replication without the need for antiviral therapy (39, 40)—further introduces that the diverse strengths of immune-mediated selection forces can reshape the configuration of the latent HIV reservoir harboring genetically intact proviruses alongside the acquired immunodeficiency syndrome (AIDS) disease progression (30, 31), refreshing the concept of HIV deep latency (or silencing).

The concept of HIV deep latency originated from the 1990s onward and was updated progressively. A deeper level of HIV latency is most likely referred to as the latent proviruses that are refractory to reactivation, already discriminating from inducible latency and supporting the presence of distinct latent MMEs. These proviruses are often associated with either epigenetic features (e.g., DNA methylation; see Section IV) or the specific chromosomal conformation (e.g., heterochromatin). These characteristics associated with HIV deep latency were unveiled by HIV IS retrieved from elite controllers with a preference for centromeric satellite DNA or in Krüppel-associated box domain-containing zinc finger (KZNF) genes (30). A similar tendency was recapitulated in individuals with HIV under prolonged ART (31, 41). In fact, HIV ISs in heterochromatin regions are already detected in early-treated individuals after 1 year on ART and are progressively enriched after 5 years on ART based on a longitudinal analysis using the acute and chronic cohort (23).

Moving forward, the observations of distinct graph isomorphism based on the Pearson distance between graph networks constructed by HIV-targeted genes retrieved between ART-treated patients and elite controllers using graph-theoretically based tools and the diverse graph evolutionary trajectories simulated by the Markov chain Monte Carlo (MCMC) method also suggest the different intrinsic properties of HIV reservoirs lying between these two types of HIV-infected individuals (42). A recent study further identified the distinct dynamics of longitudinal biomarkers and pathways related to elite controllers and viremic controllers (i.e., HIV-RNA between 50 and 10,000 c/mL): relative to elite controllers, a higher level of CRTAM, LY9, and CD6 and a lower level of VAT1 were detected in viremic controllers (43). All these recent findings strengthen the probability of the existence of distinct latent MMEs at the global level of network organization (42, 44) and the distinct textural nature of latent MMEs harboring proviruses at a deeper level of latency (43). It is worth noting that, at present, the mechanism of elite control (or the mechanism that can push proviruses to a deeper level of latency) remains unclear. The over-representation of the HLA-B*57 alleles cannot cover every elite controller (45, 46), and many of them can still be viremic and develop progressive disease (47), inferring the presence of additional mechanisms, most likely resulting from the host genome standing behind the phenotype of elite control. A more profound identification of biomarkers and genomic features that enable isolation of such unique MMEs from elite controllers will not only continuously reinforce the concept of HIV deep latency but also advance the development of a novel functional cure under the framework of the “block-and-lock” strategy (48).

Section IV—potential features related to insert-specific HIV transcription and latency reversal

The pioneer studies from Jordan and colleagues have opened a new avenue that HIV transcription is dependent on HIV IS (49). This finding observed in the experimental setting of transformed cell lines using the HIV-based reporter proviruses somehow resembles the classic biological phenomenon, known as Position Effect Variegation (50), stating that the genomic context has an influence on the expression of endogenous and foreign genes in general. The fact that HIV ISs dictate in vitro HIV gene expression has been confirmed by a series of studies (5, 51–55), showcasing the epigenetic modifications appearing at the local genomic context surrounding HIV IS play an important role in determining a provirus fate at a transcription level.

Impacts of histone modifications on the local genomic context surrounding HIV IS

A correlation between the HIV IS and the distance of HIV IS to the closest epigenetic modification has been observed (52, 55): the expression of HIV is strongly close to endogenous enhancers denoted by ChIP-seq signals (fold change over control) of H3K27ac (Fig. 1a) in the setting of Jurkat T cells. HIV ISs also influence the response of a latent provirus to latency-reversing agents (LRAs) and latency-promoting agents (LPAs). In the former treatment with LRAs, latent proviruses that integrate in the proximity to endogenous enhancer denoted by H3K27ac are more sensitive to vorinostat compared to latent proviruses subjected to phytohemagglutinin (52). Battivelli and colleagues further estimated that less than 5% of the primary CD4+ T cells with latent infections are inducible by tested LRAs, including JQ1 (56–60), panobinostat (61), and bryostatin-1 (62, 63), and observed distinct epigenetic profiles in terms of H3K27ac, monomethylation of lysine 4 on histone H3 (H3K4me1, active enhancers), trimethylation of lysine 36 on histone H3 (H3K36me3, actively transcribed gene body), trimethylation of lysine 9 on histone H3 (H3K9m3) and trimethylation of lysine 27 on histone H3 (H3K27m3) (64, 65) (both are repressive marks of transcription) associated with HIV IS retrieved from productively infected cells (PIC), reactivated latently infected cells (RLIC), and non-reactivated latently infected cells (NRLIC) (53). Intriguingly, different promoter activities from both HIV LTRs were detected when latent proviruses were subjected to different LRAs (55). In the latter treatment with LPAs, in the in vitro infection setting, although infected cells subjected to LEDGINs (66)—small-molecule inhibitors of the interaction between HIV integrase and the cellular factor lens epithelium-derived growth factor/p75 (LEDGF/p75)—enable retargeting of an HIV IS toward genomic regions that are not favorable for HIV gene expression and reactivation (67), a small fraction of retargeted proviruses remains transcriptionally active (68). This observation already suggests that perhaps a precise prediction of latent MMEs cannot be achieved based on merely HIV IS coupled with epigenetic features. Altogether, these findings pave the way for a proposition for reactivation therapies and functional cures that cocktails of drugs with complementary spectra should be developed to cover latent proviruses with different propensities toward drugs across different MMEs. In addition, systematic classification of insert-specific HIV gene expression might be a clue to lead us to the identification of distinct latent MMEs, in which proviruses demonstrate different transcriptional phenotypes even though robust models for the prediction of HIV transcription are presently unavailable (see Section V).

Fig 1.

Two-panel diagram showing HIV integration sites create molecular microenvironments based on distance to endogenous enhancers. Sense and antisense transcript competition influences viral expression with varying transcriptional noise.

HIV ISs associated with genomic features dictate HIV transcription. (a) Heuristic representation of HIV transcription (y-axis) and the distance of an HIV IS to the closest endogenous enhancers, denoted by H3K27ac. An MME characterized by a linear correlation between an HIV IS and a host regulatory element (i.e., an endogenous enhancer) determines the transcriptional phenotype of a provirus. For example, IS1 represents a provirus that integrates in the vicinity of an endogenous enhancer, defining the property of MME1, which is favorable for HIV transcription. In contrast, IS2 represents a provirus that integrates distal to an endogenous enhancer, defining the property of MME2, which is unfavorable for HIV transcription. Schematic representation is inspired by Palma, P. (69) https://BioRender.com/4la57ft. (b) Holistic representation of HIV transcription resulting from the competition between HIV sense and antisense transcripts versus MMEs. The observation that more than 60% of HIV IS retrieved from elite controllers and long-term ART-treated patients, who displayed an opposite orientation relative to the host gene, leads us to hypothesize that readthrough transcription of the host gene could facilitate HIV antisense transcription, subsequently suppressing HIV sense transcription and promoting the establishment of latent MMEs harboring proviruses at a deeper level of latency. Proviruses that integrate in MME1 demonstrate a higher level of transcription and modest transcriptional bursting (i.e., noise). In contrast, proviruses that integrate in MME2 demonstrate a modest level of transcription and intense transcriptional bursting. Blue lines illustrate sense RNA transcription; purple lines illustrate antisense RNA transcription; and red lines illustrate readthrough transcription of a host gene targeted by HIV.

Impacts of epigenetic regulation of CpG methylation

Epigenetics comprises several molecules and mechanisms that alter gene expression during a long-term period in the context of the same DNA sequence (70). These mechanisms include DNA methylation and the covalent addition of a methyl group to the fifth carbon of cytosine (71). Epigenetic modulation is extensively involved in the establishment and maintenance of HIV latency. HIV 5′LTR is occupied by two precisely positioned nucleosomes, Nuc-0 and Nuc-1, whose remodeling and modifications directly impact HIV latency (72). Their positioning is tightly bound to various histone modifications (73–77). In addition, the HIV promoter region also contains two conserved CpG islands that form DNA methylation sites in the latent state, which are modified by DNA methyltransferase 1 (DNMT1) and maintained by methyl-CpG-binding domain protein 2 (MBD2) (78–80). They can induce significant changes in the host epigenome, leading to a cellular environment more favorable to its replication and persistence (81). Accumulating studies have reported that HIV infection leads to an increment in the average genome methylation status—both hypermethylation and hypomethylation changes are observed in the host genome (82–88), which may serve as potential MMEs, in which HIV IS can be maintained under the pressure of immune-mediated selection (30, 31), consequently resulting in the persistence of proviruses at a deeper level of latency. Lastly, unique in vitro cellular models, in which proviruses exhibit phenotypic bifurcation in terms of fluctuations in HIV transcription, strengthen the hypothesis that, in some cases, the regulation of HIV transcription can be a pure epigenetic phenomenon (55, 89).

HIV transcription machinery

HIV transcription has a long and rich history of investigations and is well known to be tightly regulated by the 5′LTR promoter (90–92), with which HIV hijacks host cellular transcription factors to control its gene expression (93). In brief, upon infection, the recruited host cell transcription factors are sufficient to initiate HIV transcription; however, very low levels of full-length transcripts are produced at this stage (94, 95). To increase expression, the HIV transactivator Tat protein plays an important role by enhancing transcriptional elongation from the HIV 5’LTR promoter (96), which is referred to as the promoter ON state. Eventually, the Tat positive-feedback circuit relaxes in the OFF state, thus leading to the establishment of latency (27, 89). At present, the two-state promoter model (ON versus OFF) represents the classic model for HIV transcriptional noise, an episodic process of gene expression (97, 98), and has been applied to explain the molecular mechanism behind this bursty phenotype of gene expression. This two-state model relies on a specific regulatory architecture to determine thresholds that allow a biological system to either respond or disregard an input signal. The HIV Tat transactivation is sufficient to induce a burst of HIV 5′LTR promoter activity that leads to fluctuations in HIV gene expression (27); however, this model fails to generate a clear threshold response with deterministic bistability. In addition, this model fails to represent the physiological HIV infection condition that HIV latent infection can be established in the early stage of infection, as mentioned in Section II. All these observations imply that most likely an additional unknown determinant or mechanism is involved in governing stochastic HIV transcription. Mathematical modeling recapitulating the regulation of HIV transcription can be referred to (69, 99). Most likely, the specificity (e.g., incorporation of more parameters) of these algorithms will be necessary for a better representation of distinct latent MMEs when additional features related to unique latent MMEs are identified.

Potential role of ASTs in promoting latency

Viruses have developed various strategies to establish a latent state to ensure their persistence in their hosts. For instance, herpes viruses encode latency proteins that are responsible for switching the viral cycle from a lytic to a latent state (100). Another example is the detection of antisense transcripts, namely CMV latency-associated transcripts in bone marrow aspirating from naturally infected, healthy seropositive donors infected by human cytomegalovirus (101). Retroviruses, in contrast, are known to persist through transcriptional silencing and do not encode latency proteins. In fact, in other human retroviruses, like human T-cell leukemia virus type 1 (HTLV-1), one of the best characterized ASTs in a viral system, its antisense gene product, HTLV-1 basic leucine zipper factor (HBZ), has been proven to functionally promote the survival and proliferation of HTLV-1-infected cells, thereby influencing progression into adult T-cell leukemia/lymphoma or HTLV-1-associated myelopathy/tropical spastic paraparesis (102). HIV ASTs are supposed to suppress sense RNA transcription (103–105); however, at present, the fundamental mechanism behind the competition between sense and antisense transcripts and whether or not HIV ASTs can actively promote the establishment of HIV latency remains unclear.

Our understanding regarding HIV antisense transcription, which was first postulated in 1988 (106), remains insufficiently explored. Multiple HIV ASTs with both protein-coding (107) and non-coding functions (103–105, 108) are driven by the Tat-independent HIV 3′LTR (109–111) and compete with its sense RNA transcription (55). The presence of ASTs in unstimulated peripheral blood mononuclear cells collected from PLWH, along with the ectopic expression of ASTs that suppress HIV transcription and latency reversal (112), further suggests their natural occurrence in PLWH (113). Intriguingly, one preprint suggests that the expression of HIV ASTs is associated with the efficiency of HIV IS (114); however, further investigation is required. It is important to stress that more than 60% of HIV IS retrieved from elite controllers and long-term ART-treated patients, who displayed an opposite orientation relative to the host gene. This observation may infer that readthrough transcription of the host gene could facilitate HIV antisense transcription, subsequently suppressing HIV sense transcription and promoting the establishment of latent MMEs harboring proviruses at a deeper level of latency (Fig. 1b). In contrast, transcriptional interference occurs between a host gene readthrough transcript and HIV sense transcript (Fig. 1b), subsequently leading to the establishment of HIV latency. Nevertheless, our empirical observation also indicates that, most likely, features at the RNA level alone may be too strict (or insufficient) for the classification of stochastic HIV transcription (55).

Latency reversal and spread between cells

Current antiretroviral therapy can block new infections of susceptible cells, but cannot eliminate the virus production from cells with integrated latent proviruses. Latently infected cells that form latent reservoirs may cause viral rebound after antiretroviral therapy is interrupted, consequently impeding the efficacy of treatment. Ongoing natural reactivation of latently infected cells results in virus release in lymphoid tissue (115) with a low viremia on the order of two HIV RNA copies/mL of plasma (116, 117). Upon discontinuation of ART, exponential HIV growth rebounds within a few weeks (118, 119), aligning with a cascade of stochastic processes (120). An accurate prediction of the behavior of provirus rebound is therefore crucial for the better design of antiretroviral regimens. Ordinary differential equations, which were used to model kinetics, were applied to model HIV rebound following ART interruption more than 20 years ago (118, 119). Stochastic modeling, such as MCMC algorithms (121, 122), the Gillespie algorithm (123), and Bayesian inference (124), is also implemented in forecasting viral rebound after ART is interrupted (125, 126). A variety of predictive variables were utilized to establish models, including the decay rate of the latent reservoir in the absence of viral replication, the rate at which the latent reservoir produces actively infected cells, the probability that any one activated cell will produce a rebounding infection before its lineage dies, the net growth rate of the infection once restarted, the numbers of resting memory and latently infected CD4+ T cells as well as HIV RNA copies (125, 126). At present, the parameter related to the variety across patients is not yet frequently implemented in the model construction. A recent study, however, points out that clinical characteristics, for example, sex, influence the composition of the HIV reservoir associated with immunity (127). In the future, parameters at the population and cohort levels should also be included when predicting latent MMEs associated with latency reversal.

Section V—prediction of latent MMEs using DL approaches

A low frequency of proviruses (0.01%–0.1%) in CD4+ T cells (128) renders it difficult to precisely target latent MMEs, subsequently impairing the effectiveness of current ART. The success of an accurate prediction of latent MMEs relies not only on the understanding of the mechanisms that determine the fate of a provirus but also on a powerful tool that enables the analysis of a massive amount of sequence data covering the nature of latent MMEs from numerous tiers. DL, a subdiscipline of machine learning (ML), yielding end-to-end models (e.g., deep neural networks) to compute more complex features, is deemed to be a potential option. Several DL models and algorithms have been available, and the field is constantly evolving. In addition to fundamental models, such as convolutional neural networks (CNNs) (see Box 1; Fig. 2) and recurrent neural networks (RNNs) (129), recent innovations in DL architectures include transformers (130, 131), graph convolutional networks (GCNs) (132), capsule networks (133), generative adversarial networks (GANs) (134), and advances made in training techniques. Due to the limitation of the text length, a brief description of each model is provided in a glossary. The principal components embedded in a DL model are described in Box 1, taking CCNs as an example. In the following content, the emphasis will be placed on the discussion of the rationale and the potential workflow (Fig. 3a) for the examination and prediction of the likelihood of latent MMEs.

Box 1. Architecture of convolutional neural networks .

The design of the model’s architecture, which is referred to as the structure of the layered network, including the types of operations performed in each layer, the number of layers, and how they are connected, is crucial to achieving accurate predictions (135). A hierarchical architecture in CNNs implements the initial layer that captures local and simple features from input data sets, whereas the deeper layers (i.e., the convolution, pooling, and fully connected layers) dissect more intricate interactions across entities (135) (Fig. 2). The convolution layer is the core component in CNNs (136, 137). This layer performs a dot product between a filter, namely, kernel (Fig. 2), and a subset of the sequence matching the kernel size. Each convolution operation corresponds to a position weight matrix. Given that this model architecture can be regarded as a series of arithmetic operations applied to its input, it is imperative to represent inputs, such as DNA sequences, in a numerical format (i.e., quantitative scores) for quantitative modeling. Most commonly, one-hot encoding is used, in which each nucleotide in a sequence profile is converted to a unique binary vector of length 4, with each dimension corresponding to a nucleotide type. For example, A = [1, 0, 0, 0], T = [0, 1, 0, 0], C = [0, 0, 1, 0], and G = [0, 0, 0, 1].

The output of a neuron after the convolution operation can be described by equation 1.

outputj=act(∑t=1n(W∗X)tj+biasl) (1)

The variable act is a chosen activation function, W is the weight matrix or kernel, X is the input vector, * is the convolution operator, and n is the total number of nodes that the neuron is receiving input from.

After the convolution operation, a pooling operation may follow in a pooling layer (138). The common pooling operations are max pooling and average pooling. Afterward, the fully connected layer follows the pooling layer before output is generated (Fig. 2). Rather than choosing features manually or in a preprocessing step, CNNs adaptively learn them from the data during training and apply nonlinear transformations to map input data to informative high-dimensional representations that trivialize classification or regression (139).

Fig 2.

Architectural diagram of convolutional neural network demonstrating sequential processing from one-hot encoded input through convolution layer with N kernels, pooling layer for feature extraction, and connected layers for final classification output.

Architecture of the CNNs. CNNs are feed-forward neural networks that are used for image classification and processing with the help of provided data. A hierarchical architecture in CNNs implements the initial layer that captures local and simple features from input data sets, and the deeper layers, including the convolution, pooling, and fully connected layers, that can dissect more intricate interactions across entities. The convolution layer is the core component in CNNs. See Box 1 for details.

Fig 3.

Workflow for predicting latent MMEs in HIV cohorts using deep learning. Multi-omics features from genomics, epigenetics, transcription, and cellular states are processed through convolutional neural networks for classification.

Schematic representation of a theoretical workflow and the rationale of the construction of a DL model for the prediction of the likelihood of latent MMEs. (a) A theoretical workflow (highlighted in green boxes), consisting of the five steps, is proposed to predict the likelihood of latent MMEs using DL models. Available tools that can be used for each step are provided in blue boxes. Potential solutions to handle a small size of an HIV cohort for modeling are provided in purple boxes. CNNs, convolutional neural networks; RNNs, recurrent neural networks; LSTM, long short-term memory; GRU, gated recurrent unit; GCNs, graph convolutional networks; GANs, generative adversarial networks; RMSE, root mean squared error; SHAP values, SHapley Additive exPlanations values. (b) Multi-omics-based features obtained from various biological dimensions will be used as input, followed by the convolution, pooling, and fully connected layers, enabling a superior performance in predicting the likelihood of latent MMEs. Five groups of features appearing at different levels of the MME organization are discussed in the minireview. Please refer to the main text for details.

Use of the DL model to predict HIV IS

DL models have been frequently applied in healthcare. Application domains include medical imaging, genomics, and drug discovery, patient monitoring and care, and federated learning and privacy. With respect to the HIV field, DL models have been utilized for diagnostics, drug resistance prediction, neuroimaging, comorbidity detection, and the prediction of HIV IS (140–142). DeepHINT (Deep learning for HIV integration), which is an attention-based DL framework, enables the prediction of an HIV IS and mechanistic explanations (i.e., sequence motifs) of the detected sites based on either primary DNA sequences alone or together with the data set of ChIP-seq H3K36me3 signals (140). Attention mechanisms are particularly designed in this framework to extract important regions of input data by training an additional neural network, subsequently increasing the explainability of DL models. In principle, DeepHINT first employs multiple convolution-pooling modules to automatically learn informative sequence features from the DNA sequence 1 kilobase (kb) upstream and downstream from the HIV IS, followed by one-hot encoding, the operation of a position weight matrix, and the incorporation of the attention mechanism (140). Altogether, DNA sequences as input alone enable the prediction of an HIV IS; the addition of the H3K36me3 signal as an input leverages prediction performance (140). The feasibility of predicting HIV IS merely based on the DNA sequence surrounding HIV IS already sheds light on the possibility of predicting the likelihood of latent MMEs if HIV gene expression can also be accurately forecasted. The critical question now is whether HIV transcription (or gene expression in general) is predictable using DL models as well.

Rationale behind the application of DL models to predict the likelihood of latent MMEs

Even though current research employing DL models for the prediction of HIV latency is scarce—of note, three research articles were released using NCBI PubMed with the keywords ((HIV latency) OR (HIV latent reservoir)) AND ((deep learning) OR (deep neural networks) OR (Convolutional Neural Networks)), accessed on 6 March 2026—DL has been progressively implemented in HIV studies in the last years. In addition to the prediction of HIV IS (140), based on HIV sequence data, Steiner and colleagues applied a multilayer perceptron (MLP) (143), a bidirectional recurrent neural network (BRNN) (144), and CNNs for drug resistance prediction (145). Dampier and colleagues applied HIV-Bidirectional Encoder Representations from Transformers (BERT) (146)—a protein-based transformer model—to predict protease drug resistance, the coreceptor tropism based on the V3 loop sequence, and the presence of HIV reservoirs across anatomical sites (147). Derbel and colleagues established a deep learning framework (148), namely Rep2Mut, which is the evolutionary scale modeling protein language model, to classify the difference between wild-type HIV Tat protein sequences and mutated sequences (149). Arrigoni and colleagues applied variational autoencoder (VAE) (150)-based models to screen potential new ligands of the enzyme, which do not belong to any known class of HIV protease inhibitors (151). Powell and Davis extended the highly expressive cryoDRGN DL architecture (152, 153), namely tomoDRGN (Deep Reconstructing Generative Networks), to reveal the high-level organization of HIV capsid complexes (154). Kutsal and colleagues applied the tailored long short-term memory (LSTM) (155) VAE architecture to the discovery of new antiretroviral drugs (156). Pham and colleagues developed DeepARV, a transformer-based DL model, to predict drug-drug interactions in PLWH subjected to different antiretroviral drugs and a wide range of comedications (157).

In fact, DNA-barcode-based high-throughput technology has evidenced the effects of chromatin position on gene expression (158), aligning with the dogma of position effects (159) (see Section IV). In addition, the genome-wide mapping of autonomous promoter activity demonstrated that the transcriptional activities associated with isolated promoters can explain a significant amount (54%) of endogenous promoter activity (160). These results already established a clear mechanistic link between the primary DNA sequence of promoters and variability in gene expression levels. Since then, these massively parallel reporter assays (MPRAs) have made substantial progress (135) and provided an independent source of training data by directly measuring the ability of thousands to billions of short DNA sequences (up to ~2 kb) (161–163). Such a so-called sequence-to-expression (S2E) model exemplifies the capability of extrapolating previously unseen sequences and predicting the effect of sequence variants or generating entirely synthetic regulatory elements not present in the genome (135). Since HIV transcriptional activity is largely influenced by HIV IS and the local genomic environment, the S2E models may offer a promising approach to decipher the language of DNA sequences associated with HIV IS and efficiently predict HIV transcription and distinct MMEs.

In addition to its capacity in sequence-level prediction, DL models enable the capture of non-linear relationships between predictive variables and HIV transcription, resulting from, for example, bifurcation of proviral fate and stochastic HIV transcription (55, 89, 97, 98). Furthermore, DL models overcome the curse of dimensionality (164, 165). Their success has been exemplified in game playing (166), computer vision (167), natural language processing (168), and computational biology (169). This noticeable advance facilitates the integration of single-cell RNA-seq (scRNA-seq) data for prediction, given that the latent reservoir is extremely rare and heterogeneous (128). Methods, such as VASC (170), scVAE (171), scVDN (172), and ScInfoVAE (173), have been developed under the DL framework for the analysis of scRNA-seq data. Furthermore, GCNs, which can embed millions of single cells into meaningful low-dimensional manifolds (see the following section Step 2), are an additional option for input data at a single-cell scale. Although at present, DL models have not yet been systematically tested for their effectiveness in predicting HIV transcription and latent MMEs, the previous study based on binary logistic regression models constructed by 26 regulatory features, including lamin sub-compartment states (denoted by Hi-C), H3K27ac (denoted by ChIP-seq), and chromatin accessibility (denoted by MNase-seq), has showcased the feasibility of using AI-based approaches (174). The modest prediction outcomes (area under the receiver operating characteristics, 64.71%) from this traditional ML may be caused by the intricate nature of HIV transcription and latent MMEs (174). With the aforementioned technical breakthroughs in DL, it can be expected that DL models will offer superior predictive performance. It is important to stress that even though traditional ML, which is based on feature vectorization of input sequences, can also be applied for sequence-based prediction, DL with more advanced tokenization techniques further leverages prediction sensitivity, specificity, and accuracy. For example, Bhandari and colleagues used the frequency-based tokenization approach to enhance CNN efficiency in promoter prediction across diverse species (175). Fallahpour and colleagues designed a specialized and tailored tokenization scheme embedded in a transformer model to generate codon-optimized DNA sequences (176). Other tokenization approaches on DNA sequences, including nucleotide/protein-based, word-based, k-mer-based, and subword tokenization, can be referred to in the review from Testagrose and Boucher (177).

Theoretical workflow to predict latent MMEs using DL models

Step 1—preparation of input data sets for training

Although DL models are known for their high data demands, it continues to be difficult to pinpoint the correct sample size for the specific prediction target in the first place. With this respect, the 10-times rule (178) has been a favorite due to its simplicity of application. This rule means that the number of data sets should be 10 times more than the number of parameters embedded in a data set. Given that HIV research frequently suffers from a small cohort, one potential solution that can mitigate this issue is to leverage the quality of the input data in terms of the specificity of the parameters. For example, features precisely target proviruses at a deeper level of latency or those specific to certain LRAs or LPAs. In addition, a quality control procedure should also be implemented to filter out problematic data and outliers before training. The presently available data sets that can be used to train DL models, including (i) HIV IS mapped by a wide range of PCR-based (e.g., ligation-mediated PCR, linear amplification-mediated PCR, Integration Site Loop Amplification [179], INSPIIRED [180], LIS-seq [55, 181]) followed by high-throughput sequencing, (ii) insert-specific single provirus transcriptomics measured by B-HIVE (52, 182), (iii) the integrity of the HIV genome (intact versus defective; studies that characterize the integrity of the HIV genome are summarized in Więcek and Chen [183]), (iv) RNA-seq and host transcriptomics (e.g., available at Gene Expression Omnibus [GEO]), (v) scRNA-seq on cells from PLWH on ART using classic scRNA-seq (184), ECCITEseq (185), DOGMAseq (186), HIV-seq (187), (vi) (epi)genomic data sets (e.g., ChIP-seq, MNase-seq, ATAC-seq, HiC, and so on), (vii) HIV-human proteins interactomics data (e.g., PHISTO [188], NCBI database [189], VirusMentha [190], VirHostNet [191], HPIDB [192], Viruses.STRING [193], and so on), (viii) clinical longitudinal cohort data (longitudinal studies associated with the HIV reservoir are summarized in Chen [44]), and (ix) HIV sequence variation data (e.g., available at the Los Alamos National Laboratory HIV Databases [https://www.hiv.lanl.gov/]).

Step 2—selection of appropriate DL model architectures

An appropriate DL model can be determined based on the type of inputs, the prediction task, and computational constraints. In principle, CCNs are typically suitable for grid-like data sets (see Box 1) (194), whereas recurrent neural networks (RNNs) (129), particularly long short-term memory (LSTM) (155) or gated recurrent unit (GRU) (195) architectures, are optional for sequence-based and time-series data sets. Here, it is worth noting that network-based analysis in “omics” data sets is one of the common approaches to illustrate pathogen-host interactions and has been broadly applied to HIV research (44). With this element in mind, GCNs can serve as an option for the prediction of latent MMEs when the input data set is retrieved from scRNA-seq or HIV-host molecular interactomes. Network-embedded GCNs have become instrumental in representing complex biological networks in multi-omics integrations. In these models, each entity can be treated as a vertex, and edges unveil statistical similarity or correlation coefficients derived from “omics” data between two adjacent vertices. Unlike traditional CNNs (see Box 1), which operate on grid-like data (Fig. 2), GCNs learn by aggregating information from neighbors of individual vertices, allowing them to capture contextual signals and relational patterns within graph networks. The core GCNs update rule can be described as:

H(l+1)=σ(D−1/2A~D−1/2H(l)Θ(l)) (2)

where à = A + I adds self-loops to include information from individual vertices, D is the degree matrix, H(l) represents vertex features at layer l, Θ(I) contains trainable weights, and σ is a non-linear activation function (132). When stacked, multi-layer GCNs allow information to flow across the graph, achieving DL. GCNs exploit both the network topology and feature attributes to classify vertices, enabling interpretable and efficient learning. Attention-based GCNs further extend their capacity by adjusting edge weights based on feature relevance, resulting in more robust and interpretable predictions (196). Whether or not GCNs and their relative models can facilitate identifying potential graphlets (197, 198)—a set of driver vertices defined as core–peripheral structures and considered to hold paramount importance to underpin the topology of a network—will be a question of interest and requires further investigation. If achievable, these DL-based approaches can retrieve the most significant attributes for the classification and prediction of the likelihood of distinct latent MMEs. Overall, suggested DL methods for different types of genomic and omics data, as well as strengths and limitations, are summarized in Table 1.

TABLE 1.

Systematic summary of suggested DL models for various input omics data

Input data type Input data format DL methods Representative models Key tasks Strengths Limitations
DNA sequence-based One-hot encoded nucleotide sequences CNNs; Transformer (130, 131); RNNs (129); Long Short-Term Memory (LSTM) (155); Hybrid CNN-RNN DeepSEA (199); DeepBind (200); DNABERT/ DNABERT-2 (201, 202); Nucleotide transformer (203) Transcription factor binding prediction; variant effect prediction; promoter/enhancer identification Capture of local sequence motifs; modeling long-range genomic dependencies; multi-task learning across regulatory features High memory usage for long sequences; limited interpretability of learned features; context-specificity issues
Transcriptomics Gene expression matrices (bulk RNA-seq counts or TPM) Autoencoder/VAE (150); GANs (134); MLP (143); DNNs (137); GNNs scVI (204); ZINB-WaVE (205); DeepLIFT (206) Gene expression prediction; dimensionality reduction; subtype classification Handling high-dimensional sparse data; effective for batch correction Sensitive to batch effects; requires large sample sizes
Long-read sequence Raw nanopore ionic current signals/PacBio HiFi reads (FASTQ/BAM) RNNs (129); LSTM (155); Transformer (130, 131); CNNs; Conditional random fields (CRF) (207) + DNNs (137) Bonito/Doradoa; PEPPER-Margin-DeepVariant (208) Basecalling; structural variant detection;
isoform identification; methylation calling
Resolving complex structural variants and full-length transcripts; detection of base modifications simultaneously Higher raw error rates versus short reads; computationally intensive; requires GPU for real-time basecalling
scRNA-seq UMI count matrices (cells × genes); sparse format VAE (150); Graph transformer; GNNs; Diffusion models (209) scVI (204); Geneformer (210); scBERT (211) Cell clustering and annotation; trajectory and pseudotime inference; batch correction; dropout imputation Single-cell resolution enables cell-type discovery; foundation models transferable across tissues Extreme sparsity and dropout noise; the presence of biological variation and technical noise
Epigenetics and genomics ChIP-seq/ATAC-seq signal tracks; WGBS methylation arrays; Hi-C contact matrices CNNs; Transformer (130, 131); Multi-task DNNs; Attention-based models DeepSEA (199); Enformer (212); DeepMEL (213) Chromatin accessibility; histone modification prediction; DNA methylation prediction; 3D genome and TAD modeling Integration of multi-omics signals; decoding regulatory grammar; long-range enhancer-promoter interactions Context-specific regulatory patterns; class imbalance in peak calling; high data heterogeneity
Network-based Adjacency matrices (correlation coefficients) and edge lists; biological knowledge graphs; co-expression networks GCNs/Graph attention networks (GAT) (214); Graph transformer; Variational graph AE; Message passing NN (MPNN) (215) DTINet (216); SEAL (217) Protein-protein interaction prediction; drug-target interaction; gene regulatory network inference; pathway over-representation analysis Exploiting relational interactions between biological entities; integration of heterogeneous data sources Incomplete and noisy interaction networks; scalability to whole-genome graphs; over-smoothing in deep GNNs
Longitudinal cohort Time-series omics matrices; EHRb records with irregular timestamps; repeated-measures cohort data LSTM (155); GRU (195); Temporal transformer; Neural ODE (218) T-LSTM (219); ODE-RNN (220); State space models (Mamba) (221) Disease progression modeling; time-series gene expression analysis; patient trajectory prediction; microbiome temporal dynamics Modeling temporal dependencies and dynamic biological processes; handling variable-length sequences Irregular sampling intervals; missing time points; small longitudinal cohort sizes; temporal batch effects; inter- and intra-patient variations
a

Bonito/Dorado (ONT basecalling) Oxford Nanopore Technologies (2021–present). Bonito and Dorado: open-source basecallers for Nanopore sequencing https://github.com/nanoporetech/bonito; https://github.com/nanoporetech/dorado.

b

EHR: electronic health record.

Step 3—optimization of the training strategy

Training DL models is an iterative process and requires careful monitoring and adjustment. In this step, it is critical to select an appropriate loss function—a mathematical way to measure the quality of a model prediction—that aligns with prediction tasks. Cross-entropy loss (222) is standard for classification, whereas mean squared error and mean absolute error can be applied to regression. In principle, prediction accuracy can be improved by training the model with relevant features of high complexity. It is also important to stress that, in this step, updating model parameters to optimize the algorithm and implementing regularization techniques to prevent overfitting can be carried out.

Step 4—validation of the prediction performance

Rigorous evaluation of predictive accuracy, ensuring the experimental quality, is essential, as performed in all artificial intelligence (AI)-based studies. Classical indicators include precision, recall, F1 score, ROC curves, and area under the curve (AUC), R-squared, mean absolute error, and root mean squared error. Cross-validation is recommended for a small input data set.

Step 5—leveraging interpretation and scientific insights

In addition to completing prediction tasks, it is crucial that DL models contribute to extracting interpretable insights from trained models to validate our scientific question: Does the HIV latent reservoir possess distinct MMEs, and are they predictable? The performance of the feature importance analysis, such as permutation importance (223) and SHAP values (224), enabling the quantification of how much predictive variables contribute to prediction, is recommended.

At present, interpretation accuracy using DL models is challenging to measure due to the lack of appropriate gold standards (225). The straightforward strategy to improve the interpretability of prediction is the integration of multidimensional data sets for training prediction models (Fig. 3b). It is also worth noting that P-NET (226)—one of the most prominent biology-inspired models trained on patient mutation data—already exemplified the feasibility of preclinical discovery and clinical prediction in prostate cancer using a neural network architecture; the implementation of strengthening control methods in a neural network can still leverage its interpretability (227). In addition, HIV clinical data sets covering the HIV type 1 genomic diversity at the population level and immunity-relevant parameters should also be taken into account. The cohort study based on both partial HIV pol gene and viral near full-length genome sequences retrieved from HIV type 1 subtype B demonstrated a heritability of ~10%–20% for the HIV latent reservoir under suppressive ART (228). In parallel, clinical features retrieved from the longitudinal cohort can be taken into account because the dynamics of immunological parameters alongside HIV/AIDS disease progression have been characterized (229, 230). Implementation of longitudinal features may aid in recapitulating the evolution of latent MMEs. Another possible strategy to strengthen the explainability of prediction using DL models is the introduction of attention mechanisms, which are particularly designed to extract important regions of input data by training an additional neural network that learns the relative importance of each input position from local features (231) and has been implemented in the prediction of HIV IS (140) (see the previous paragraph in Section V).

It is important to note that although multidimensional data sets are critical to achieve better predictive accuracy, how to choose an appropriately sized CNN should be prudently examined. This issue can be explicated by the bias-variance dilemma (232)—the trade-off between a model’s ability to accurately recapitulate the underlying data patterns (low bias) and its tolerance to the variations in the training data (high variance). A large neural network may risk overfitting the data, resulting in poor performance. A proposed solution for finding the optimal network size is to continually calculate both the bias and the variance components of the error during training.

DISCUSSION

The nature of biased HIV IS associated with diverse levels of HIV transcription, allowing us to conceive the presence of distinct latent MMEs. This concept can be supported by clinical and experimental findings showing that DNA sequence, coupled with genomic and epigenetic features, reservoir cell states, and the integrity of the proviral genome, are tightly bound to the regulation of HIV transcription and latency reversal. Although it remains elusive whether the likelihood of distinct latent MMEs can be precisely predicted, the success in the prediction of HIV IS (140), and the accessibility of the S2E models (135) underscore the potential of the prediction of latent MMEs in the near future.

To date, significant effort has been devoted to identifying potential biomarkers and developing new technologies that enable more effective probing of latent MMEs. However, given that a low frequency of proviruses in CD4+ T cells (128, 233) is present, exploring a richer array of features that can directly capture the clinical phenomena of HIV infections remains difficult. DL models that automatically extract low-level features and generalize them into higher-level features may offer a promising approach for predicting latent MMEs from limited input from a small clinical cohort. It is important to stress that ML-based models with improved domain-specific learning curves enable a robust prediction with minimum data set sizes of the inputs ranging between 500 and 1,000, which is affordable by the majority of HIV cohort studies (234). Furthermore, GCNs (132) (see the previous section, Step 2) have demonstrated strong potential to capture biologically meaningful structures and offer superior performance by reducing overfitting in small-cohort biomedical applications (235). Forthcoming efforts should be made toward the discovery of features that specify the transcriptional program of a provirus (productive replication versus inducible and deep latency), rather than reinforcing or maintaining their transcriptional states, thereby enabling a clear discrepancy across distinct latent MMEs.

As a final remark, cell-type-specific gene expression predictions based solely on primary sequences remain a considerable challenge for the field (13). An increasing number of immune cells that either directly or indirectly interact with HIV infections and elicit various immune responses (including immunological memory) that may influence the configuration of latent MMEs should also be taken into account when building a model. The improvements in computing capacity in this context may enhance predictive accuracy for distinct cell types of the HIV reservoir and HIV reservoir compartmentations.

CONCLUDING REMARKS AND FUTURE PERSPECTIVES

DL models are capable of integrating multi-modal biological data—from HIV IS, reservoir cellular state, the integrity of the HIV genome, HIV transcription, and latency reversal—positioning it uniquely to decode the complex and heterogeneous nature of latent MMEs. As previously mentioned, at present, it remains difficult to precisely define latent MMEs. Most likely, the observation of latent MMEs can be identified separately for each feature or characterized as an ensemble of all features. Therefore, it is crucial to carefully choose or integrate various features before engaging in DL modeling, as this can result in differing predictive results. Encouragingly, DL models can capture the non-linear interactions between features retrieved from different biological dimensions that collectively define the likelihood of distinct latent MMEs. A correlation between observed phenomena related to HIV/AIDS disease progression and a wide range of features resulting from a variety of “omics” approaches has been unveiled. More efforts of future research should focus on illuminating which features identified from latent MMEs are truly causative versus correlative. In this respect, DL models offer an opportunity to retrieve crucial features represented in distinct latent MMEs and lead us to explore more about the nature of latent MMEs from a mechanistic point of view. Apart from the prediction of latent MMEs, when more “omics,” clinical and patient-specific data sets are available for DL in the near future, more converging trends, including (i) establishing a comprehensive single-cell atlas of HIV reservoirs at a single-virus level through integrated single-cell “omics” modalities and near-full-length proviral sequencing (37), (ii) tracking the evolutionary trajectory of latent MMEs and those harboring proviruses at a deeper level of latency based on clinical longitudinal data sets, (iii) novel antiretroviral drugs discovery and screening, (iv) AI-based medical decision making for diagnosis and therapies, and (v) constructing digital twins-driven (236, 237) patient-specific models of the HIV reservoir, can be anticipated. Such knowledge is expected to guide us to precise HIV interventions and the development of personalized HIV regimens.

Glossary

Deep learning (DL)

A class of machine-learning approaches capable of identifying highly complex patterns in large datasets (reviewed in reference 135).

End-to-end models

Machine learning models that embed the entire data-processing pipeline to transform raw input data into predictions without requiring a preprocessing step (reviewed in reference 137).

Deep neural networks

A wide class of machine learning models with a design that is loosely based on biological neural networks (reviewed in reference 137).

Convolutional neural networks

A neural network architecture using convolutional layers that extract local patterns at different spatial hierarchies (reviewed in reference 135).

Recurrent neural networks

RNNs are designed for sequential data processing and are crucial for tasks involving time-series or language data (129).

Transformers

A neural network architecture based on the concept of self-attention that weighs the importance of different parts of the input, allowing long-range dependencies to be captured (reviewed in references 130, 131).

Graph convolutional networks

Neural networks that process graph-structured data, generalizing the concept of convolution from images to graphs. The same neural network is applied to each node and edge in the graph.

Capsule networks

It is designed to enhance model hierarchical relationships and the processing of information by using groups of neurons known as “capsules,” which handle more complex tasks than the typical neurons in CNNs (133).

Generative adversarial networks

It consists of two interconnected neural networks—the generator and the discriminator—and engages in a continuous game-theoretic competition during training (134).

Attention-based deep learning

A deep learning model embeds an additional layer, so-called the attention layer. This layer takes the feature vector after convolution-pooling operations as input, and then computes a score indicating whether the neural network shall pay attention to the sequence features at that position.

Attention mechanisms

A particularly designed layer (i.e., the attention layer; see the definition above) to extract important regions of input data by training an additional neural network that learns the relative importance of each input position from local features (231).

One-hot coding

A technique for converting categorical data into a numerical format that machine-learning algorithms can process.

Position weight matrix

Representation of motifs in aligned DNA sequences as matrices that indicate the importance at each nucleotide position (reviewed in reference [135]).

Multilayer perceptron

It is one of the most widely used types of neural networks for supervised learning tasks (143).

Bidirectional recurrent neural network

It is a type of recurrent neural network architecture that processes sequential data in both forward and backward directions simultaneously, allowing the model to capture context from both past and future states at any given point in a sequence.

Sequence-to-expression (S2E) model

This model enables the prediction of gene expression from DNA sequence alone (reviewed in reference 135).

Long short-term memory

It is a special type of RNNs designed to learn and remember information over long sequences of data (155).

Gated recurrent unit

It is a type of RNNs and is used to gate mechanisms to selectively update the hidden state at each time step, allowing remembering important information (195).

Autoencoder/variational autoencoder

It is an artificial neural network architecture and can be viewed as two coupled, but independently parameterized models—the encoder or recognition model, and the decoder or generative model (150).

Graph neural networks

It is a class of DL models designed to perform inference on data structured as graphs—that is, data represented by vertices (entities) and edges (correlations between entities).

Conditional random fields

It is a type of discriminative probabilistic graphical model used to model the conditional probability of a set of output variables given a set of input variables, particularly well-suited for structured prediction tasks where outputs are interdependent (207).

Diffusion models

It is a class of generative DL models that learn to generate data, such as images, audio, video, and so on (209).

Message passing NN

It is a general and unified framework for GNNs that formalizes how information is propagated and aggregated across graph structures (215).

Neural ODE

It is a class of DL models that parameterizes the derivative of a hidden state using a neural network, rather than defining discrete layer-by-layer transformations (218).

The convolution layer

A neural network layer that processes data stored in n-dimensional arrays, such as images. When applied to DNA sequences, a convolutional layer can be interpreted as a set of position weight matrices (see the definition above) scanned across the sequence (reviewed in reference [137]).

The pooling layer

This layer aggregates the activations in contiguous bins across the positional axis, typically taking the maximal or average activation for each channel—an axis other than one of the positional axes (reviewed in reference 137).

The fully connected layer

A neural network layer, in which every input contributes to the computation of every output (reviewed in reference 135).

Kernel

A filter, which is a small matrix that can detect specific patterns in the input sequence through the process of convolution (reviewed in reference 135).

Contributor Information

Heng-Chang Chen, Email: heng-chang.chen@port.lukasiewicz.gov.pl.

Herman W. Favoreel, Universiteit Gent, Merelbeke, Belgium

REFERENCES

  • 1. Tang Y, Chaillon A, Gianella S, Wong LM, Li D, Simermeyer TL, Porrachia M, Ignacio C, Woodworth B, Zhong D, et al. 2023. Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy. J Clin Invest 133:e167417. doi: 10.1172/JCI167417 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Rheinberger M, Costa AL, Kampmann M, Glavas D, Shytaj IL, Sreeram S, Penzo C, Tibroni N, Garcia-Mesa Y, Leskov K, et al. 2023. Genomic profiling of HIV-1 integration in microglia cells links viral integration to the topologically associated domains. Cell Rep 42:112110. doi: 10.1016/j.celrep.2023.112110 [DOI] [PubMed] [Google Scholar]
  • 3. Veenhuis RT, Abreu CM, Costa PAG, Ferreira EA, Ratliff J, Pohlenz L, Shirk EN, Rubin LH, Blankson JN, Gama L, et al. 2023. Monocyte-derived macrophages contain persistent latent HIV reservoirs. Nat Microbiol 8:833–844. doi: 10.1038/s41564-023-01349-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Schröder ARW, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. 2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110:521–529. doi: 10.1016/s0092-8674(02)00864-4 [DOI] [PubMed] [Google Scholar]
  • 5. Lewinski MK, Bisgrove D, Shinn P, Chen H, Hoffmann C, Hannenhalli S, Verdin E, Berry CC, Ecker JR, Bushman FD. 2005. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J Virol 79:6610–6619. doi: 10.1128/JVI.79.11.6610-6619.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Michel F, Crucifix C, Granger F, Eiler S, Mouscadet J-F, Korolev S, Agapkina J, Ziganshin R, Gottikh M, Nazabal A, et al. 2009. Structural basis for HIV‐1 DNA integration in the human genome, role of the LEDGF/P75 cofactor. EMBO J 28:980–991. doi: 10.1038/emboj.2009.41 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Mitchell RS, Beitzel BF, Schroder ARW, Shinn P, Chen H, Berry CC, Ecker JR, Bushman FD. 2004. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2:E234. doi: 10.1371/journal.pbio.0020234 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Marini B, Kertesz-Farkas A, Ali H, Lucic B, Lisek K, Manganaro L, Pongor S, Luzzati R, Recchia A, Mavilio F, et al. 2015. Nuclear architecture dictates HIV-1 integration site selection. Nature 521:227–231. doi: 10.1038/nature14226 [DOI] [PubMed] [Google Scholar]
  • 9. Lucic B, Chen H-C, Kuzman M, Zorita E, Wegner J, Minneker V, Wang W, Fronza R, Laufs S, Schmidt M, et al. 2019. Spatially clustered loci with multiple enhancers are frequent targets of HIV-1 integration. Nat Commun 10:4059. doi: 10.1038/s41467-019-12046-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Penzo C, Özel I, Martinovic M, Kuzman M, Glavas D, Stanic M, Reichenbach T, Müller TG, Rheinberger M, Godarzi N, et al. 2025. Aquarius helicase facilitates HIV-1 integration into R-loop enriched genomic regions. Nat Microbiol 10:2306–2322. doi: 10.1038/s41564-025-02089-2 [DOI] [PubMed] [Google Scholar]
  • 11. Tan-Wong SM, Dhir S, Proudfoot NJ. 2019. R-loops promote antisense transcription across the mammalian genome. Mol Cell 76:600–616. doi: 10.1016/j.molcel.2019.10.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Niehrs C, Luke B. 2020. Regulatory R-loops as facilitators of gene expression and genome stability. Nat Rev Mol Cell Biol 21:167–178. doi: 10.1038/s41580-019-0206-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Agarwal V, Shendure J. 2020. Predicting mRNA abundance directly from genomic sequence using deep convolutional neural networks. Cell Rep 31:107663. doi: 10.1016/j.celrep.2020.107663 [DOI] [PubMed] [Google Scholar]
  • 14. Zhang Z, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA, Reinhart TA, Rogan M, Cavert W, Miller CJ, et al. 1999. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 286:1353–1357. doi: 10.1126/science.286.5443.1353 [DOI] [PubMed] [Google Scholar]
  • 15. Siliciano RF, Greene WC. 2011. HIV latency. Cold Spring Harb Perspect Med 1:a007096. doi: 10.1101/cshperspect.a007096 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Coffin J, Swanstrom R. 2013. HIV pathogenesis: dynamics and genetics of viral populations and infected cells. Cold Spring Harb Perspect Med 3:a012526. doi: 10.1101/cshperspect.a012526 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 94:13193–13197. doi: 10.1073/pnas.94.24.13193 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, et al. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295–1300. doi: 10.1126/science.278.5341.1295 [DOI] [PubMed] [Google Scholar]
  • 19. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, et al. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512–517. doi: 10.1038/8394 [DOI] [PubMed] [Google Scholar]
  • 20. Chang JT, Wherry EJ, Goldrath AW. 2014. Molecular regulation of effector and memory T cell differentiation. Nat Immunol 15:1104–1115. doi: 10.1038/ni.3031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Kulpa DA, Chomont N. 2015. HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide? J Virus Erad 1:59–66. doi: 10.1016/S2055-6640(20)30490-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Barton K, Winckelmann A, Palmer S. 2016. HIV-1 reservoirs during suppressive therapy. Trends Microbiol 24:345–355. doi: 10.1016/j.tim.2016.01.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Struyve T, Pardons M, De Clercq J, Termote L, Lambrechts L, Noppe Y, Lichterfeld M, Rutsaert S, Vandekerckhove L. 2025. Evolution of the HIV-1 integration site landscape and inducible reservoir in early-treated people. PLoS Pathog 21:e1013702. doi: 10.1371/journal.ppat.1013702 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Pearson R, Kim YK, Hokello J, Lassen K, Friedman J, Tyagi M, Karn J. 2008. Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. J Virol 82:12291–12303. doi: 10.1128/JVI.01383-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Tyagi M, Pearson RJ, Karn J. 2010. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol 84:6425–6437. doi: 10.1128/JVI.01519-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Vanhamel J, Bruggemans A, Debyser Z. 2019. Establishment of latent HIV-1 reservoirs: what do we really know? J Virus Erad 5:3–9. doi: 10.1016/S2055-6640(20)30275-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Razooky BS, Pai A, Aull K, Rouzine IM, Weinberger LS. 2015. A hardwired HIV latency program. Cell 160:990–1001. doi: 10.1016/j.cell.2015.02.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Rouzine IM, Weinberger AD, Weinberger LS. 2015. An evolutionary role for HIV latency in enhancing viral transmission. Cell 160:1002–1012. doi: 10.1016/j.cell.2015.02.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Reda O, Monde K, Sugata K, Rahman A, Sakhor W, Rajib SA, Sithi SN, Tan BJY, Niimura K, Motozono C, et al. 2024. HIV-Tocky system to visualize proviral expression dynamics. Commun Biol 7:344. doi: 10.1038/s42003-024-06025-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Jiang C, Lian X, Gao C, Sun X, Einkauf KB, Chevalier JM, Chen SMY, Hua S, Rhee B, Chang K, et al. 2020. Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature 585:261–267. doi: 10.1038/s41586-020-2651-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Einkauf KB, Lee GQ, Gao C, Sharaf R, Sun X, Hua S, Chen SM, Jiang C, Lian X, Chowdhury FZ, Rosenberg ES, Chun T-W, Li JZ, Yu XG, Lichterfeld M. 2019. Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. J Clin Invest 129:988–998. doi: 10.1172/JCI124291 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Descours B, Petitjean G, López-Zaragoza J-L, Bruel T, Raffel R, Psomas C, Reynes J, Lacabaratz C, Levy Y, Schwartz O, et al. 2017. CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses. Nature 543:564–567. doi: 10.1038/nature21710 [DOI] [PubMed] [Google Scholar]
  • 33. Sun W, Gao C, Hartana CA, Osborn MR, Einkauf KB, Lian X, Bone B, Bonheur N, Chun T-W, Rosenberg ES, et al. 2023. Phenotypic signatures of immune selection in HIV-1 reservoir cells. Nature 614:309–317. doi: 10.1038/s41586-022-05538-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Dubé M, Tastet O, Dufour C, Sannier G, Brassard N, Delgado G-G, Pagliuzza A, Richard C, Nayrac M, Routy J-P, et al. 2023. Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIV-specific CD4+ and CD8+ T cells. Cell Host Microbe 31:1507–1522. doi: 10.1016/j.chom.2023.08.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Ho Y-C, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DIS, Lai J, Blankson JN, Siliciano JD, Siliciano RF. 2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540–551. doi: 10.1016/j.cell.2013.09.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Bruner KM, Murray AJ, Pollack RA, Soliman MG, Laskey SB, Capoferri AA, Lai J, Strain MC, Lada SM, Hoh R, et al. 2016. Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat Med 22:1043–1049. doi: 10.1038/nm.4156 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Hiener B, Horsburgh BA, Eden J-S, Barton K, Schlub TE, Lee E, von Stockenstrom S, Odevall L, Milush JM, Liegler T, et al. 2017. Identification of genetically intact HIV-1 proviruses in specific CD4+ T cells from effectively treated participants. Cell Rep 21:813–822. doi: 10.1016/j.celrep.2017.09.081 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Imamichi H, Smith M, Adelsberger JW, Izumi T, Scrimieri F, Sherman BT, Rehm CA, Imamichi T, Pau A, Catalfamo M, et al. 2020. Defective HIV-1 proviruses produce viral proteins. Proc Natl Acad Sci USA 117:3704–3710. doi: 10.1073/pnas.1917876117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Deeks SG, Walker BD. 2007. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27:406–416. doi: 10.1016/j.immuni.2007.08.010 [DOI] [PubMed] [Google Scholar]
  • 40. Migueles SA, Connors M. 2010. Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. JAMA 304:194–201. doi: 10.1001/jama.2010.925 [DOI] [PubMed] [Google Scholar]
  • 41. Einkauf KB, Osborn MR, Gao C, Sun W, Sun X, Lian X, Parsons EM, Gladkov GT, Seiger KW, Blackmer JE, et al. 2022. Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses. Cell 185:266–282. doi: 10.1016/j.cell.2021.12.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Wiśniewski J, Więcek K, Ali H, Pyrc K, Kula-Păcurar A, Wagner M, Chen H-C. 2024. Distinguishable topology of the task-evoked functional genome networks in HIV-1 reservoirs. iScience 27:111222. doi: 10.1016/j.isci.2024.111222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Vadaq N, Groenendijk AL, Dos Santos JC, Mehta K, Wit F, Vos W, Blaauw MJT, van Eekeren LE, Lambrechts L, Rutsaert S, et al. 2026. Longitudinal plasma proteomic signatures of elite and viremic spontaneous HIV controllers. Nat Commun 17:1173. doi: 10.1038/s41467-025-67939-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Chen H-C. 2025. From network biology to immunity: potential longitudinal biomarkers for targeting the network topology of the HIV reservoir. J Transl Med 23:906. doi: 10.1186/s12967-025-06919-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Bailey JR, O’Connell K, Yang H-C, Han Y, Xu J, Jilek B, Williams TM, Ray SC, Siliciano RF, Blankson JN. 2008. Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol 82:7395–7410. doi: 10.1128/JVI.00800-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Blankson JN, Bailey JR, Thayil S, Yang H-C, Lassen K, Lai J, Gandhi SK, Siliciano JD, Williams TM, Siliciano RF. 2007. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 81:2508–2518. doi: 10.1128/JVI.02165-06 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, et al. 2000. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 97:2709–2714. doi: 10.1073/pnas.050567397 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Kessing CF, Nixon CC, Li C, Tsai P, Takata H, Mousseau G, Ho PT, Honeycutt JB, Fallahi M, Trautmann L, et al. 2017. In vivo suppression of HIV rebound by didehydro-Cortistatin A, a “block-and-lock” strategy for HIV-1 treatment. Cell Rep 21:600–611. doi: 10.1016/j.celrep.2017.09.080 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Jordan A, Defechereux P, Verdin E. 2001. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J 20:1726–1738. doi: 10.1093/emboj/20.7.1726 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Muller HJ. 1930. Types of visible variations induced by X-rays in Drosophila. J Genet 22:299–334. doi: 10.1007/BF02984195 [DOI] [Google Scholar]
  • 51. Sherrill-Mix S, Lewinski MK, Famiglietti M, Bosque A, Malani N, Ocwieja KE, Berry CC, Looney D, Shan L, Agosto LM, et al. 2013. HIV latency and integration site placement in five cell-based models. Retrovirology (Auckl) 10:90. doi: 10.1186/1742-4690-10-90 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Chen H-C, Martinez JP, Zorita E, Meyerhans A, Filion GJ. 2017. Position effects influence HIV latency reversal. Nat Struct Mol Biol 24:47–54. doi: 10.1038/nsmb.3328 [DOI] [PubMed] [Google Scholar]
  • 53. Battivelli E, Dahabieh MS, Abdel-Mohsen M, Svensson JP, Tojal Da Silva I, Cohn LB, Gramatica A, Deeks S, Greene WC, Pillai SK, et al. 2018. Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T cells. eLife 7:e34655. doi: 10.7554/eLife.34655 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Collora JA, Ho Y-C. 2023. Integration site–dependent HIV-1 promoter activity shapes host chromatin conformation. Genome Res 33:891–906. doi: 10.1101/gr.277698.123 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Więcek K, Wiśniewski J, Chen H-C. 2025. The influence of HIV sense and antisense transcripts on stochastic HIV transcription and reactivation. Comput Struct Biotechnol J 27:3528–3546. doi: 10.1016/j.csbj.2025.08.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. 2010. Selective inhibition of BET bromodomains. Nature 468:1067–1073. doi: 10.1038/nature09504 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, Bradner J, Sebastiani P, Margolis DM, Montano M. 2012. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 92:1147–1154. doi: 10.1189/jlb.0312165 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Zhu J, Gaiha GD, John SP, Pertel T, Chin CR, Gao G, Qu H, Walker BD, Elledge SJ, Brass AL. 2012. Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep 2:807–816. doi: 10.1016/j.celrep.2012.09.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Boehm D, Calvanese V, Dar RD, Xing S, Schroeder S, Martins L, Aull K, Li P-C, Planelles V, Bradner JE, et al. 2013. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 12:452–462. doi: 10.4161/cc.23309 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Li Z, Guo J, Wu Y, Zhou Q. 2013. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res 41:277–287. doi: 10.1093/nar/gks976 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61. Rasmussen T, Tolstrup M, Winckelmann A, Østergaard L, Schmeltz Søgaard O. 2013. Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother 9:790–799. doi: 10.4161/hv.23202 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. del Real G, Jiménez-Baranda S, Mira E, Lacalle RA, Lucas P, Gómez-Moutón C, Alegret M, Peña JM, Rodríguez-Zapata M, Alvarez-Mon M, et al. 2004. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 200:541–547. doi: 10.1084/jem.20040061 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63. Mehla R, Bivalkar-Mehla S, Zhang R, Handy I, Albrecht H, Giri S, Nagarkatti P, Nagarkatti M, Chauhan A. 2010. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One 5:e11160. doi: 10.1371/journal.pone.0011160 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Shlyueva D, Stampfel G, Stark A. 2014. Transcriptional enhancers: from properties to genome-wide predictions. Nat Rev Genet 15:272–286. doi: 10.1038/nrg3682 [DOI] [PubMed] [Google Scholar]
  • 65. Kumar A, Darcis G, Van Lint C, Herbein G. 2015. Epigenetic control of HIV-1 post integration latency: implications for therapy. Clin Epigenet 7:103. doi: 10.1186/s13148-015-0137-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66. Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, Marchand D, Bardiot D, Van der Veken NJ, Van Remoortel B, Strelkov SV, et al. 2010. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 6:442–448. doi: 10.1038/nchembio.370 [DOI] [PubMed] [Google Scholar]
  • 67. Vranckx LS, Demeulemeester J, Saleh S, Boll A, Vansant G, Schrijvers R, Weydert C, Battivelli E, Verdin E, Cereseto A, et al. 2016. LEDGIN-mediated inhibition of integrase-LEDGF/p75 interaction reduces reactivation of residual latent HIV. EBioMedicine 8:248–264. doi: 10.1016/j.ebiom.2016.04.039 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Vansant G, Chen H-C, Zorita E, Trejbalová K, Miklík D, Filion G, Debyser Z. 2020. The chromatin landscape at the HIV-1 provirus integration site determines viral expression. Nucleic Acids Res 48:7801–7817. doi: 10.1093/nar/gkaa536 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Rasi G, Emili E, Conway JM, Cotugno N, Palma P. 2025. Mathematical modeling and mechanisms of HIV latency for personalized anti latency therapies. NPJ Syst Biol Appl 11:64. doi: 10.1038/s41540-025-00538-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70. Cavalli G, Heard E. 2019. Advances in epigenetics link genetics to the environment and disease. Nature 571:489–499. doi: 10.1038/s41586-019-1411-0 [DOI] [PubMed] [Google Scholar]
  • 71. Fitz-James MH, Cavalli G. 2022. Molecular mechanisms of transgenerational epigenetic inheritance. Nat Rev Genet 23:325–341. doi: 10.1038/s41576-021-00438-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72. Khan S, Iqbal M, Tariq M, Baig SM, Abbas W. 2018. Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins. Clin Epigenetics 10:14. doi: 10.1186/s13148-018-0441-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73. du Chéné I, Basyuk E, Lin Y, Triboulet R, Knezevich A, Chable‐Bessia C, Mettling C, Baillat V, Reynes J, Corbeau P, et al. 2007. Suv39H1 and HP1γ are responsible for chromatin‐mediated HIV‐1 transcriptional silencing and post‐integration latency. EMBO J 26:424–435. doi: 10.1038/sj.emboj.7601517 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Imai K, Togami H, Okamoto T. 2010. Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J Biol Chem 285:16538–16545. doi: 10.1074/jbc.M110.103531 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75. Friedman J, Cho W-K, Chu CK, Keedy KS, Archin NM, Margolis DM, Karn J. 2011. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J Virol 85:9078–9089. doi: 10.1128/JVI.00836-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Hakre S, Chavez L, Shirakawa K, Verdin E. 2011. Epigenetic regulation of HIV latency. Curr Opin HIV AIDS 6:19–24. doi: 10.1097/COH.0b013e3283412384 [DOI] [PubMed] [Google Scholar]
  • 77. Boehm D, Jeng M, Camus G, Gramatica A, Schwarzer R, Johnson JR, Hull PA, Montano M, Sakane N, Pagans S, et al. 2017. SMYD2-mediated histone methylation contributes to HIV-1 latency. Cell Host Microbe 21:569–579. doi: 10.1016/j.chom.2017.04.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78. Blazkova J, Trejbalova K, Gondois-Rey F, Halfon P, Philibert P, Guiguen A, Verdin E, Olive D, Van Lint C, Hejnar J, et al. 2009. CpG methylation controls reactivation of HIV from latency. PLoS Pathog 5:e1000554. doi: 10.1371/journal.ppat.1000554 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. 2009. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 5:e1000495. doi: 10.1371/journal.ppat.1000495 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80. Trejbalová K, Kovářová D, Blažková J, Machala L, Jilich D, Weber J, Kučerová D, Vencálek O, Hirsch I, Hejnar J. 2016. Development of 5‘ LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals. Clin Epigenet 8:19. doi: 10.1186/s13148-016-0185-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81. Arumugam T, Ramphal U, Adimulam T, Chinniah R, Ramsuran V. 2021. Deciphering DNA methylation in HIV infection. Front Immunol 12:795121. doi: 10.3389/fimmu.2021.795121 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82. Zhang Y, Li S-K, Yi Yang K, Liu M, Lee N, Tang X, Wang H, Liu L, Chen Z, Zhang C, Wang J, Kwok-Wing Tsui S. 2015. Whole genome methylation array reveals the down-regulation of IGFBP6 and SATB2 by HIV-1. Sci Rep 5:10806. doi: 10.1038/srep10806 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83. Zhang X, Justice AC, Hu Y, Wang Z, Zhao H, Wang G, Johnson EO, Emu B, Sutton RE, et al. 2016. Epigenome-wide differential DNA methylation between HIV-infected and uninfected individuals. Epigenetics 11:750–760. doi: 10.1080/15592294.2016.1221569 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84. Bogoi RN, de Pablo A, Valencia E, Martín-Carbonero L, Moreno V, Vilchez-Rueda HH, Asensi V, Rodriguez R, Toledano V, Rodés B. 2018. Expression profiling of chromatin-modifying enzymes and global DNA methylation in CD4+ T cells from patients with chronic HIV infection at different HIV control and progression states. Clin Epigenetics 10:20. doi: 10.1186/s13148-018-0448-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85. Shiau S, Strehlau R, Wang S, Violari A, Do C, Patel F, Liberty A, Krupska I, Arpadi SM, Foca M, et al. 2019. Distinct epigenetic profiles in children with perinatally-acquired HIV on antiretroviral therapy. Sci Rep 9:10495. doi: 10.1038/s41598-019-46930-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86. Oriol-Tordera B, Berdasco M, Llano A, Mothe B, Gálvez C, Martinez-Picado J, Carrillo J, Blanco J, Duran-Castells C, Ganoza C, et al. 2020. Methylation regulation of antiviral host factors, interferon stimulated genes (ISGs) and T-cell responses associated with natural HIV control. PLoS Pathog 16:e1008678. doi: 10.1371/journal.ppat.1008678 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87. Esteban-Cantos A, Rodríguez-Centeno J, Silla JC, Barruz P, Sánchez-Cabo F, Saiz-Medrano G, Nevado J, Mena-Garay B, Jiménez-González M, et al. , NEAT001/ANRS143 study group . 2023. Effect of HIV infection and antiretroviral therapy initiation on genome-wide DNA methylation patterns. EBioMedicine 88:104434. doi: 10.1016/j.ebiom.2022.104434 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88. Taryma-Leśniak O, Bińkowski J, Mielczak K, Aksak-Wąs B, Karasińska-Cieślak M, Sobalska-Kwapis M, Strapagiel D, Parczewski M, Wojdacz TK. 2025. Changes of methylation at enhancers appear to be essential for HIV infection progression. Clin Epigenetics 17:104. doi: 10.1186/s13148-025-01910-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89. Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV. 2005. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 122:169–182. doi: 10.1016/j.cell.2005.06.006 [DOI] [PubMed] [Google Scholar]
  • 90. Nabel G, Baltimore D. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326:711–713. doi: 10.1038/326711a0 [DOI] [PubMed] [Google Scholar]
  • 91. Kinoshita S, Su L, Amano M, Timmerman LA, Kaneshima H, Nolan GP. 1997. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity 6:235–244. doi: 10.1016/s1074-7613(00)80326-x [DOI] [PubMed] [Google Scholar]
  • 92. Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, Nabel GJ. 1997. Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science 275:523–527. doi: 10.1126/science.275.5299.523 [DOI] [PubMed] [Google Scholar]
  • 93. Ne E, Palstra R-J, Mahmoudi T. 2018. Transcription: insights from the HIV-1 promoter. Int Rev Cell Mol Biol 335:191–243. doi: 10.1016/bs.ircmb.2017.07.011 [DOI] [PubMed] [Google Scholar]
  • 94. Zhang Z, Klatt A, Gilmour DS, Henderson AJ. 2007. Negative elongation factor NELF represses human immunodeficiency virus transcription by pausing the RNA polymerase II complex. J Biol Chem 282:16981–16988. doi: 10.1074/jbc.M610688200 [DOI] [PubMed] [Google Scholar]
  • 95. Natarajan M, Schiralli Lester GM, Lee C, Missra A, Wasserman GA, Steffen M, Gilmour DS, Henderson AJ. 2013. Negative elongation factor (NELF) coordinates RNA polymerase II pausing, premature termination, and chromatin remodeling to regulate HIV transcription. J Biol Chem 288:25995–26003. doi: 10.1074/jbc.M113.496489 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96. Lassen K, Han Y, Zhou Y, Siliciano J, Siliciano RF. 2004. The multifactorial nature of HIV-1 latency. Trends Mol Med 10:525–531. doi: 10.1016/j.molmed.2004.09.006 [DOI] [PubMed] [Google Scholar]
  • 97. Austin DW, Allen MS, McCollum JM, Dar RD, Wilgus JR, Sayler GS, Samatova NF, Cox CD, Simpson ML. 2006. Gene network shaping of inherent noise spectra. Nature 439:608–611. doi: 10.1038/nature04194 [DOI] [PubMed] [Google Scholar]
  • 98. Dar RD, Razooky BS, Singh A, Trimeloni TV, McCollum JM, Cox CD, Simpson ML, Weinberger LS. 2012. Transcriptional burst frequency and burst size are equally modulated across the human genome. Proc Natl Acad Sci USA 109:17454–17459. doi: 10.1073/pnas.1213530109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99. D’Orso I, Forst CV. 2023. Mathematical models of HIV-1 dynamics, transcription, and latency. Viruses 15:2119. doi: 10.3390/v15102119 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100. Lekstrom-Himes JA, Wang K, Pesnicak L, Krause PR, Straus SE. 1998. The comparative biology of latent herpes simplex virus type 1 and type 2 infections: latency-associated transcript promoter activity and expression in vitro and in infected mice. J Neurovirol 4:27–37. doi: 10.3109/13550289809113479 [DOI] [PubMed] [Google Scholar]
  • 101. Kondo K, Xu J, Mocarski ES. 1996. Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc Natl Acad Sci USA 93:11137–11142. doi: 10.1073/pnas.93.20.11137 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102. Bangham CRM, Miura M, Kulkarni A, Matsuoka M. 2019. Regulation of latency in the human T cell leukemia virus, HTLV-1. Annu Rev Virol 6:365–385. doi: 10.1146/annurev-virology-092818-015501 [DOI] [PubMed] [Google Scholar]
  • 103. Saayman S, Ackley A, Turner A-MW, Famiglietti M, Bosque A, Clemson M, Planelles V, Morris KV. 2014. An HIV-encoded antisense long noncoding RNA epigenetically regulates viral transcription. Mol Ther 22:1164–1175. doi: 10.1038/mt.2014.29 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104. Zapata JC, Campilongo F, Barclay RA, DeMarino C, Iglesias-Ussel MD, Kashanchi F, Romerio F. 2017. The human immunodeficiency virus 1 ASP RNA promotes viral latency by recruiting the polycomb repressor complex 2 and promoting nucleosome assembly. Virology (Auckl) 506:34–44. doi: 10.1016/j.virol.2017.03.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105. Kobayashi-Ishihara M, Terahara K, Martinez JP, Yamagishi M, Iwabuchi R, Brander C, Ato M, Watanabe T, Meyerhans A, Tsunetsugu-Yokota Y. 2018. HIV LTR-driven antisense RNA by itself has regulatory function and may curtail virus reactivation from latency. Front Microbiol 9:1066. doi: 10.3389/fmicb.2018.01066 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106. Miller D. 1988. HIV and social psychiatry. Br Med Bull 44:130–148. doi: 10.1093/oxfordjournals.bmb.a072236 [DOI] [PubMed] [Google Scholar]
  • 107. Gholizadeh Z, Iqbal MS, Li R, Romerio F. 2021. The HIV-1 antisense gene ASP: the new kid on the block. Vaccines (Basel) 9:513. doi: 10.3390/vaccines9050513 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108. Kobayashi-Ishihara M, Yamagishi M, Hara T, Matsuda Y, Takahashi R, Miyake A, Nakano K, Yamochi T, Ishida T, Watanabe T. 2012. HIV-1-encoded antisense RNA suppresses viral replication for a prolonged period. Retrovirology (Auckl) 9:38. doi: 10.1186/1742-4690-9-38 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109. Michael NL, Vahey MT, d’Arcy L, Ehrenberg PK, Mosca JD, Rappaport J, Redfield RR. 1994. Negative-strand RNA transcripts are produced in human immunodeficiency virus type 1-infected cells and patients by a novel promoter downregulated by Tat. J Virol 68:979–987. doi: 10.1128/jvi.68.2.979-987.1994 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110. Bentley K, Deacon N, Sonza S, Zeichner S, Churchill M. 2004. Mutational analysis of the HIV-1 LTR as a promoter of negative sense transcription. Arch Virol 149:2277–2294. doi: 10.1007/s00705-004-0386-8 [DOI] [PubMed] [Google Scholar]
  • 111. Landry S, Halin M, Lefort S, Audet B, Vaquero C, Mesnard J-M, Barbeau B. 2007. Detection, characterization and regulation of antisense transcripts in HIV-1. Retrovirology (Auckl) 4. doi: 10.1186/1742-4690-4-71 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112. Li R, Daneshvar K, Ji X, Pleet M, Igbinosun G, Iqbal MS, Kashanchi F, Mullen AC, Romerio F. 2025. Suppression of HIV-1 transcription and latency reversal via ectopic expression of the viral antisense transcript AST. Sci Adv 11:eadu8014. doi: 10.1126/sciadv.adu8014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113. Capoferri AA, Sklutuis R, Famuyiwa TO, Pathak S, Li R, Rausch JW, Luke BT, Hoh R, Deeks SG, Mellors JW, Coffin JM, et al. 2025. In vivo detection of antisense HIV-1 transcripts in untreated and ART-treated individuals. Life Sci Alliance 8:e202503204. doi: 10.26508/lsa.202503204 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114. Tedbury PR, Mahboubi D, Puray-Chavez M, Shah R, Ukah OB, Wahoski CC, Fadel HJ, Poeschla EM, Gao X, McFadden WM. 2024. Disruption of LEDGF/p75-directed integration derepresses antisense transcription of the HIV-1 genome. bioRxiv. doi: 10.1101/2024.12.06.627169 [DOI]
  • 115. Rothenberger MK, Keele BF, Wietgrefe SW, Fletcher CV, Beilman GJ, Chipman JG, Khoruts A, Estes JD, Anderson J, Callisto SP, et al. 2015. Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proc Natl Acad Sci USA 112:E1126–E1134. doi: 10.1073/pnas.1414926112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Rock-Kress D, Dewar R, et al. 2007. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 3:e46. doi: 10.1371/journal.ppat.0030046 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS. 2008. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 105:3879–3884. doi: 10.1073/pnas.0800050105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118. Davey RT Jr, Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, Natarajan V, Lempicki RA, Adelsberger JW, Miller KD, et al. 1999. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 96:15109–15114. doi: 10.1073/pnas.96.26.15109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119. Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Zayat MK, Marfil S, Negredo E, Sirera G, Tural C, Clotet B. 2000. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 14:397–403. doi: 10.1097/00002030-200003100-00013 [DOI] [PubMed] [Google Scholar]
  • 120. Hataye JM, Casazza JP, Best K, Liang CJ, Immonen TT, Ambrozak DR, Darko S, Henry AR, Laboune F, Maldarelli F, et al. 2019. Principles governing establishment versus collapse of HIV-1 cellular spread. Cell Host Microbe 26:748–763. doi: 10.1016/j.chom.2019.10.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121. Metropolis N, Ulam S. 1949. The Monte Carlo method. J Am Stat Assoc 44:335–341. doi: 10.1080/01621459.1949.10483310 [DOI] [PubMed] [Google Scholar]
  • 122. Metropolis N, Rosenbluth AW, Rosenbluth MN, Teller AH, Teller E. 1953. Equation of state calculations by fast computing machines. J Chem Phys 21:1087–1092. doi: 10.1063/1.1699114 [DOI] [PubMed] [Google Scholar]
  • 123. Gillespie DT. 1977. Exact stochastic simulation of coupled chemical reactions. J Phys Chem 81:2340–2361. doi: 10.1021/j100540a008 [DOI] [Google Scholar]
  • 124. Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, Brubaker MA, Guo J, Li P, Riddell A. 2017. Stan: a probabilistic programming language. J Stat Softw 76:1. doi: 10.18637/jss.v076.i01 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125. Hataya Y, Kurata M, Murabe K, Hakata T, Fujimoto K, Iwakura T, Yamasaki T, Matsuoka N. 2025. Effects of cabozantinib on plasma adrenocorticotropic hormone and serum cortisol levels in patients with metastatic renal cell carcinoma: a retrospective study. BMC Endocr Disord 25:248. doi: 10.1186/s12902-025-02072-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126. Hill AL, Rosenbloom DIS, Fu F, Nowak MA, Siliciano RF. 2014. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci USA 111:13475–13480. doi: 10.1073/pnas.1406663111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127. Tan TS, Gao C, Hochroth AS, Vela L, Carrere L, Kalavacherla S, Hong S, Lancien M, Naasz CM, Niesar A, et al. 2025. Sex differences in HIV-1 reservoir cell selection are linked to altered innate immune profiles. Sci Transl Med 17:eadu7154. doi: 10.1126/scitranslmed.adu7154 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9:727–728. doi: 10.1038/nm880 [DOI] [PubMed] [Google Scholar]
  • 129. Tsantekidis A, Passalis N, Tefas A. 2022. Recurrent neural networks, p 101–115. In Deep learning for robot perception and cognition. Elsevier. [Google Scholar]
  • 130. Vaswani A, Shazeer N, Parmar N, Uszkoreit J, Jones L, Gomez AN, Kaiser L, Polosukhin I. 2017. Attention is all you need. arXiv. doi: 10.48550/arXiv.1706.03762 [DOI]
  • 131. Han K, Wang Y, Chen H, Chen X, Guo J, Liu Z, Tang Y, Xiao A, Xu C, Xu Y, et al. 2023. A survey on vision transformer. IEEE Trans Pattern Anal Mach Intell 45:87–110. doi: 10.1109/TPAMI.2022.3152247 [DOI] [PubMed] [Google Scholar]
  • 132. Kipf TN, Welling M. 2016. Semi-supervised classification with graph convolutional networks. arXiv. doi: 10.48550/arXiv.1609.02907 [DOI]
  • 133. Sabour S, Frosst N, Hinton GE. 2017. Dynamic routing between capsules. arXiv. doi: 10.48550/arXiv.1710.09829 [DOI]
  • 134. Bengesi S, El-Sayed H, Sarker MDK, Houkpati Y, Irungu J, Oladunni T. 2024. Advancements in generative AI: a comprehensive review of GANs, GPT, autoencoders, diffusion model, and transformers. IEEE Access 12:69812–69837. doi: 10.1109/ACCESS.2024.3397775 [DOI] [Google Scholar]
  • 135. Barbadilla-Martínez L, Klaassen N, van Steensel B, de Ridder J. 2025. Predicting gene expression from DNA sequence using deep learning models. Nat Rev Genet 26:666–680. doi: 10.1038/s41576-025-00841-2 [DOI] [PubMed] [Google Scholar]
  • 136. LeCun Y, Bengio Y, Hinton G. 2015. Deep learning. Nature 521:436–444. doi: 10.1038/nature14539 [DOI] [PubMed] [Google Scholar]
  • 137. Eraslan G, Avsec Ž, Gagneur J, Theis FJ. 2019. Deep learning: new computational modelling techniques for genomics. Nat Rev Genet 20:389–403. doi: 10.1038/s41576-019-0122-6 [DOI] [PubMed] [Google Scholar]
  • 138. Indolia S, Goswami AK, Mishra SP, Asopa P. 2018. Conceptual understanding of convolutional neural network- a deep learning approach. Procedia Comput Sci 132:679–688. doi: 10.1016/j.procs.2018.05.069 [DOI] [Google Scholar]
  • 139. Bengio Y, Courville A, Vincent P. 2013. Representation learning: a review and new perspectives. IEEE Trans Pattern Anal Mach Intell 35:1798–1828. doi: 10.1109/TPAMI.2013.50 [DOI] [PubMed] [Google Scholar]
  • 140. Hu H, Xiao A, Zhang S, Li Y, Shi X, Jiang T, Zhang L, Zhang L, Zeng J. 2019. DeepHINT: understanding HIV-1 integration via deep learning with attention. Bioinformatics 35:1660–1667. doi: 10.1093/bioinformatics/bty842 [DOI] [PubMed] [Google Scholar]
  • 141. Turbé V, Herbst C, Mngomezulu T, Meshkinfamfard S, Dlamini N, Mhlongo T, Smit T, Cherepanova V, Shimada K, Budd J. 2021. Deep learning of HIV field-based rapid tests. Nat Med 27:1165–1170. doi: 10.1038/s41591-021-01384-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 142. Jin R, Zhang L. 2025. AI applications in HIV research: advances and future directions. Front Microbiol 16:1541942. doi: 10.3389/fmicb.2025.1541942 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 143. Tamouridou AA, Alexandridis TK, Pantazi XE, Lagopodi AL, Kashefi J, Kasampalis D, Kontouris G, Moshou D. 2017. Application of multilayer perceptron with automatic relevance determination on weed mapping using UAV multispectral imagery. Sensors (Basel) 17:2307. doi: 10.3390/s17102307 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 144. Schuster M, Paliwal KK. 1997. Bidirectional recurrent neural networks. IEEE Trans Signal Process 45:2673–2681. doi: 10.1109/78.650093 [DOI] [Google Scholar]
  • 145. Steiner MC, Gibson KM, Crandall KA. 2020. Drug resistance prediction using deep learning techniques on HIV-1 sequence data. Viruses 12:560. doi: 10.3390/v12050560 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 146. Elnaggar A, Heinzinger M, Dallago C, Rehawi G, Wang Y, Jones L, Gibbs T, Feher T, Angerer C, Steinegger M, et al. 2022. ProtTrans: toward understanding the language of life through self-supervised learning. IEEE Trans Pattern Anal Mach Intell 44:7112–7127. doi: 10.1109/TPAMI.2021.3095381 [DOI] [PubMed] [Google Scholar]
  • 147. Dampier W, Link RW, Earl JP, Collins M, De Souza DR, Koser K, Nonnemacher MR, Wigdahl B. 2022. HIV- bidirectional encoder representations from transformers: a set of pretrained transformers for accelerating HIV deep learning tasks. Front Virol 2. doi: 10.3389/fviro.2022.880618 [DOI] [Google Scholar]
  • 148. Meier J, Rao R, Verkuil R, Liu J, Sercu T, Rives A. 2021. Language models enable zero-shot prediction of the effects of mutations on protein function. bioRxiv. doi: 10.1101/2021.07.09.450648 [DOI]
  • 149. Derbel H, Giacoletto CJ, Benjamin R, Chen G, Schiller MR, Liu Q. 2023. Accurate prediction of transcriptional activity of single missense variants in HIV Tat with deep learning. Int J Mol Sci 24:6138. doi: 10.3390/ijms24076138 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 150. Kingma DP, Welling M. 2013. Auto-encoding variational bayes. arXiv. doi: 10.48550/arXiv.1312.6114 [DOI]
  • 151. Arrigoni R, Santacroce L, Ballini A, Palese LL. 2023. AI-aided search for new HIV-1 protease ligands. Biomolecules 13:858. doi: 10.3390/biom13050858 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 152. Zhong ED, Bepler T, Berger B, Davis JH. 2021. CryoDRGN: reconstruction of heterogeneous cryo-EM structures using neural networks. Nat Methods 18:176–185. doi: 10.1038/s41592-020-01049-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 153. Kinman LF, Powell BM, Zhong ED, Berger B, Davis JH. 2023. Uncovering structural ensembles from single-particle cryo-EM data using cryoDRGN. Nat Protoc 18:319–339. doi: 10.1038/s41596-022-00763-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 154. Powell BM, Davis JH. 2024. Learning structural heterogeneity from cryo-electron sub-tomograms with tomoDRGN. Nat Methods 21:1525–1536. doi: 10.1038/s41592-024-02210-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 155. Hochreiter S, Schmidhuber J. 1997. Long short-term memory. Neural Comput 9:1735–1780. doi: 10.1162/neco.1997.9.8.1735 [DOI] [PubMed] [Google Scholar]
  • 156. Kutsal M, Ucar F, Kati N. 2024. Computational drug discovery on human immunodeficiency virus with a customized long short-term memory variational autoencoder deep-learning architecture. CPT Pharmacometrics Syst Pharmacol 13:308–316. doi: 10.1002/psp4.13085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 157. Pham T, Ghafoor M, Grañana-Castillo S, Marzolini C, Gibbons S, Khoo S, Chiong J, Wang D, Siccardi M. 2024. DeepARV: ensemble deep learning to predict drug-drug interaction of clinical relevance with antiretroviral therapy. NPJ Syst Biol Appl 10:48. doi: 10.1038/s41540-024-00374-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 158. Akhtar W, de Jong J, Pindyurin AV, Pagie L, Meuleman W, de Ridder J, Berns A, Wessels LFA, van Lohuizen M, van Steensel B. 2013. Chromatin position effects assayed by thousands of reporters integrated in parallel. Cell 154:914–927. doi: 10.1016/j.cell.2013.07.018 [DOI] [PubMed] [Google Scholar]
  • 159. Elgin SCR, Reuter G. 2013. Position-effect variegation, heterochromatin formation, and gene silencing in Drosophila. Cold Spring Harb Perspect Biol 5:a017780. doi: 10.1101/cshperspect.a017780 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 160. van Arensbergen J, FitzPatrick VD, de Haas M, Pagie L, Sluimer J, Bussemaker HJ, van Steensel B. 2017. Genome-wide mapping of autonomous promoter activity in human cells. Nat Biotechnol 35:145–153. doi: 10.1038/nbt.3754 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 161. Trauernicht M, Martinez-Ara M, van Steensel B. 2020. Deciphering gene regulation using massively parallel reporter assays. Trends Biochem Sci 45:90–91. doi: 10.1016/j.tibs.2019.10.006 [DOI] [PubMed] [Google Scholar]
  • 162. Gallego Romero I, Lea AJ. 2023. Leveraging massively parallel reporter assays for evolutionary questions. Genome Biol 24:26. doi: 10.1186/s13059-023-02856-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 163. Zheng Y, VanDusen NJ. 2023. Massively parallel reporter assays for high-throughput in vivo analysis of cis-regulatory elements. J Cardiovasc Dev Dis 10:144. doi: 10.3390/jcdd10040144 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 164. Bach F. 2017. Breaking the curse of dimensionality with convex neural networks. arXiv. doi: 10.48550/arXiv.1412.8690 [DOI]
  • 165. Wainwright MJ. 2019. High-dimensional statistics: a non-asymptotic viewpoint. Cambridge University Press. [Google Scholar]
  • 166. Silver D, Huang A, Maddison CJ, Guez A, Sifre L, van den Driessche G, Schrittwieser J, Antonoglou I, Panneershelvam V, Lanctot M, et al. 2016. Mastering the game of Go with deep neural networks and tree search. Nature 529:484–489. doi: 10.1038/nature16961 [DOI] [PubMed] [Google Scholar]
  • 167. Voulodimos A, Doulamis N, Doulamis A, Protopapadakis E. 2018. Deep learning for computer vision: a brief review. Comput Intell Neurosci 2018:1–13. doi: 10.1155/2018/7068349 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 168. Achiam J, Adler S, Agarwal S, Ahmad L, Akkaya I, Aleman FL, Almeida D, Altenschmidt J, Altman S, et al. , OpenAI . 2023. GPT-4 technical report. arXiv. doi: 10.48550/arXiv.2303.08774 [DOI]
  • 169. Tunyasuvunakool K, Adler J, Wu Z, Green T, Zielinski M, Žídek A, Bridgland A, Cowie A, Meyer C, Laydon A, et al. 2021. Highly accurate protein structure prediction for the human proteome. Nature 596:590–596. doi: 10.1038/s41586-021-03828-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 170. Wang D, Gu J. 2018. VASC: dimension reduction and visualization of single-cell RNA-seq data by deep variational autoencoder. Genomics Proteomics Bioinformatics 16:320–331. doi: 10.1016/j.gpb.2018.08.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 171. Grønbech CH, Vording MF, Timshel PN, Sønderby CK, Pers TH, Winther O. 2020. scVAE: variational auto-encoders for single-cell gene expression data. Bioinformatics 36:4415–4422. doi: 10.1093/bioinformatics/btaa293 [DOI] [PubMed] [Google Scholar]
  • 172. Hu H, Feng Z, Shuai XS, Lyu J, Li X, Lin H, Shuai J. 2023. Identifying SARS-CoV-2 infected cells with scVDN. Front Microbiol 14:1236653. doi: 10.3389/fmicb.2023.1236653 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 173. Pan W, Long F, Pan J. 2023. ScInfoVAE: interpretable dimensional reduction of single cell transcription data with variational autoencoders and extended mutual information regularization. BioData Min 16:17. doi: 10.1186/s13040-023-00333-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 174. Ruess H, Lee J, Guzman C, Malladi VS, D’Orso I. 2022. Decoding human genome regulatory features that influence HIV-1 proviral expression and fate through an integrated genomics approach. Bioinform Biol Insights 16:11779322211072333. doi: 10.1177/11779322211072333 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 175. Bhandari N, Khare S, Walambe R, Kotecha K. 2021. Comparison of machine learning and deep learning techniques in promoter prediction across diverse species. PeerJ Comput Sci 7:e365. doi: 10.7717/peerj-cs.365 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 176. Fallahpour A, Gureghian V, Filion GJ, Lindner AB, Pandi A. 2025. CodonTransformer: a multispecies codon optimizer using context-aware neural networks. Nat Commun 16:3205. doi: 10.1038/s41467-025-58588-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 177. Testagrose C, Boucher C. 2025. Tokenization and deep learning architectures in genomics: a comprehensive review. Comput Struct Biotechnol J 27:3547–3555. doi: 10.1016/j.csbj.2025.07.038 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 178. Hair JF, Ringle CM, Sarstedt M. 2011. PLS-SEM: indeed a silver bullet. J Mark Theory Pract 19:139–152. doi: 10.2753/MTP1069-6679190202 [DOI] [Google Scholar]
  • 179. Wagner TA, McLaughlin S, Garg K, Cheung CYK, Larsen BB, Styrchak S, Huang HC, Edlefsen PT, Mullins JI, Frenkel LM. 2014. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345:570–573. doi: 10.1126/science.1256304 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 180. Sherman E, Nobles C, Berry CC, Six E, Wu Y, Dryga A, Malani N, Male F, Reddy S, Bailey A, et al. 2017. INSPIIRED: a pipeline for quantitative analysis of sites of new DNA integration in cellular genomes. Mol Ther Methods Clin Dev 4:39–49. doi: 10.1016/j.omtm.2016.11.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 181. Więcek K, Wiśniewski J, Chen H-C. 2026. An in vitro transcription-based protocol for mapping HIV integration sites using lentiviral integration site sequencing. STAR Protoc 7:104284. doi: 10.1016/j.xpro.2025.104284 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 182. Chen H-C, Zorita E, Filion GJ. 2018. Using barcoded HIV ensembles (B-HIVE) for single provirus transcriptomics. Curr Protoc Mol Biol 122:e56. doi: 10.1002/cpmb.56 [DOI] [PubMed] [Google Scholar]
  • 183. Więcek K, Chen H-C. 2023. Understanding latent HIV-1 reservoirs through host genomics approaches. iScience 26:108342. doi: 10.1016/j.isci.2023.108342 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 184. Geretz A, Ehrenberg PK, Clifford RJ, Laliberté A, Prelli Bozzo C, Eiser D, Kundu G, Yum LK, Apps R, Creegan M, et al. 2023. Single-cell transcriptomics identifies prothymosin α restriction of HIV-1 in vivo. Sci Transl Med 15:eadg0873. doi: 10.1126/scitranslmed.adg0873 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 185. Collora JA, Liu R, Pinto-Santini D, Ravindra N, Ganoza C, Lama JR, Alfaro R, Chiarella J, Spudich S, Mounzer K, et al. 2022. Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T cell clones. Immunity 55:1013–1031. doi: 10.1016/j.immuni.2022.03.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 186. Wei Y, Davenport TC, Collora JA, Ma HK, Pinto-Santini D, Lama J, Alfaro R, Duerr A, Ho Y-C. 2023. Single-cell epigenetic, transcriptional, and protein profiling of latent and active HIV-1 reservoir revealed that IKZF3 promotes HIV-1 persistence. Immunity 56:2584–2601. doi: 10.1016/j.immuni.2023.10.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 187. Frouard J, Telwatte S, Luo X, Gill N, Thomas R, Arneson D, Roychoudhury P, Butte AJ, Wong JK, Hoh R, et al. 2026. HIV-seq reveals gene expression differences between HIV-transcribing cells from viremic and suppressed people with HIV. Nat Commun 17:1540. doi: 10.1038/s41467-026-68797-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 188. Durmuş Tekir S, Çakır T, Ardıç E, Sayılırbaş AS, Konuk G, Konuk M, Sarıyer H, Uğurlu A, Karadeniz İ, Özgür A, Sevilgen FE, et al. 2013. PHISTO: pathogen–host interaction search tool. Bioinformatics 29:1357–1358. doi: 10.1093/bioinformatics/btt137 [DOI] [PubMed] [Google Scholar]
  • 189. Ako-Adjei D, Fu W, Wallin C, Katz KS, Song G, Darji D, Brister JR, Ptak RG, Pruitt KD. 2015. HIV-1, human interaction database: current status and new features. Nucleic Acids Res 43:D566–D570. doi: 10.1093/nar/gku1126 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 190. Calderone A, Licata L, Cesareni G. 2015. VirusMentha: a new resource for virus-host protein interactions. Nucleic Acids Res 43:D588–D592. doi: 10.1093/nar/gku830 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 191. Guirimand T, Delmotte S, Navratil V. 2015. VirHostNet 2.0: surfing on the web of virus/host molecular interactions data. Nucleic Acids Res 43:D583–D587. doi: 10.1093/nar/gku1121 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 192. Ammari MG, Gresham CR, McCarthy FM, Nanduri B. 2016. HPIDB 2.0: a curated database for host–pathogen interactions. Database (Oxford) 2016:baw103. doi: 10.1093/database/baw103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 193. Cook HV, Doncheva NT, Szklarczyk D, von Mering C, Jensen LJ. 2018. Viruses.STRING: a virus-host protein-protein interaction database. Viruses 10:519. doi: 10.3390/v10100519 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 194. He K, Zhang X, Ren S, Sun J. 2015. Deep residual learning for image recognition. arXiv. doi: 10.48550/arXiv.1512.03385 [DOI]
  • 195. Cho K, van Merrienboer B, Gulcehre C, Bahdanau D, Bougares F, Schwenk H, Bengio Y. 2014. Learning phrase representations using RNN encoder–decoder for statistical machine translation. Proceedings of the 2014 Conference on Empirical Methods in Natural Language Processing (EMNLP). Association for Computational Linguistics, Stroudsburg, PA, USA [Google Scholar]
  • 196. Guo H, Lv X, Li Y, Li M. 2023. Attention-based GCN integrates multi-omics data for breast cancer subtype classification and patient-specific gene marker identification. Brief Funct Genomics 22:463–474. doi: 10.1093/bfgp/elad013 [DOI] [PubMed] [Google Scholar]
  • 197. Pržulj N, Corneil DG, Jurisica I. 2004. Modeling interactome: scale-free or geometric? Bioinformatics 20:3508–3515. doi: 10.1093/bioinformatics/bth436 [DOI] [PubMed] [Google Scholar]
  • 198. Yaveroğlu ÖN, Malod-Dognin N, Davis D, Levnajic Z, Janjic V, Karapandza R, Stojmirovic A, Pržulj N. 2014. Revealing the hidden language of complex networks. Sci Rep 4:4547. doi: 10.1038/srep04547 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 199. Zhou J, Troyanskaya OG. 2015. Predicting effects of noncoding variants with deep learning-based sequence model. Nat Methods 12:931–934. doi: 10.1038/nmeth.3547 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 200. Alipanahi B, Delong A, Weirauch MT, Frey BJ. 2015. Predicting the sequence specificities of DNA- and RNA-binding proteins by deep learning. Nat Biotechnol 33:831–838. doi: 10.1038/nbt.3300 [DOI] [PubMed] [Google Scholar]
  • 201. Ji Y, Zhou Z, Liu H, Davuluri RV. 2021. DNABERT: pre-trained bidirectional encoder representations from transformers model for DNA-language in genome. Bioinformatics 37:2112–2120. doi: 10.1093/bioinformatics/btab083 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 202. Zhou Z, Ji Y, Li W, Dutta P, Davuluri R, Liu H. 2023. DNABERT-2: efficient foundation model and benchmark for multi-species genome. arXiv. doi: 10.48550/arXiv.2306.15006 [DOI]
  • 203. Dalla-Torre H, Gonzalez L, Mendoza-Revilla J, Lopez Carranza N, Grzywaczewski AH, Oteri F, Dallago C, Trop E, de Almeida BP, Sirelkhatim H, et al. 2025. Nucleotide transformer: building and evaluating robust foundation models for human genomics. Nat Methods 22:287–297. doi: 10.1038/s41592-024-02523-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 204. Lopez R, Regier J, Cole MB, Jordan MI, Yosef N. 2018. Deep generative modeling for single-cell transcriptomics. Nat Methods 15:1053–1058. doi: 10.1038/s41592-018-0229-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 205. Risso D, Perraudeau F, Gribkova S, Dudoit S, Vert J-P. 2018. A general and flexible method for signal extraction from single-cell RNA-seq data. Nat Commun 9:284. doi: 10.1038/s41467-017-02554-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 206. Shrikumar A, Greenside P, Kundaje A. 2017. Learning important features through propagating activation differences. arXiv. doi: 10.48550/arXiv.1704.02685 [DOI]
  • 207. Lafferty JD, McCallum A, Pereira F. 2001. Conditional random fields: probabilistic models for segmenting and labeling sequence data. International Conference on Machine Learning. [Google Scholar]
  • 208. Shafin K, Pesout T, Chang P-C, Nattestad M, Kolesnikov A, Goel S, Baid G, Kolmogorov M, Eizenga JM, Miga KH, et al. 2021. Haplotype-aware variant calling with PEPPER-Margin-DeepVariant enables high accuracy in nanopore long-reads. Nat Methods 18:1322–1332. doi: 10.1038/s41592-021-01299-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 209. Yang L, Zhang Z, Song Y, Hong S, Xu R, Zhao Y, Zhang W, Cui B, Yang M-H. 2024. Diffusion models: a comprehensive survey of methods and applications. ACM Comput Surv 56:1–39. doi: 10.1145/3626235 [DOI] [Google Scholar]
  • 210. Theodoris CV, Xiao L, Chopra A, Chaffin MD, Al Sayed ZR, Hill MC, Mantineo H, Brydon EM, Zeng Z, Liu XS, et al. 2023. Transfer learning enables predictions in network biology. Nature 618:616–624. doi: 10.1038/s41586-023-06139-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 211. Yang F, Wang W, Wang F, Fang Y, Tang D, Huang J, Lu H, Yao J. 2022. scBERT as a large-scale pretrained deep language model for cell type annotation of single-cell RNA-seq data. Nat Mach Intell 4:852–866. doi: 10.1038/s42256-022-00534-z [DOI] [Google Scholar]
  • 212. Avsec Ž, Agarwal V, Visentin D, Ledsam JR, Grabska-Barwinska A, Taylor KR, Assael Y, Jumper J, Kohli P, Kelley DR. 2021. Effective gene expression prediction from sequence by integrating long-range interactions. Nat Methods 18:1196–1203. doi: 10.1038/s41592-021-01252-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 213. The language of genetics. 2021. Nat Genet 53:1519–1519. doi: 10.1038/s41588-021-00965-1 [DOI] [PubMed] [Google Scholar]
  • 214. Veličković P, Cucurull G, Casanova A, Romero A, Liò P, Bengio Y. 2017. Graph attention networks. arXiv. doi: 10.48550/arXiv.1710.10903 [DOI]
  • 215. Gilmer J, Schoenholz SS, Riley PF, Vinyals O, Dahl GE. 2017. Neural message passing for quantum chemistry. arXiv. doi: 10.48550/arXiv.1704.01212 [DOI]
  • 216. Luo Y, Zhao X, Zhou J, Yang J, Zhang Y, Kuang W, Peng J, Chen L, Zeng J. 2017. A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information. Nat Commun 8:573. doi: 10.1038/s41467-017-00680-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 217. Lee C, Seok M, Jin J, Cho Y, Park E. 2025. SEAL: scaling to emphasize attention for long-context retrieval. arXiv. doi: 10.48550/arXiv.2501.15225 [DOI]
  • 218. Chen RT, Rubanova Y, Bettencourt J, Duvenaud DK. 2018. Neural ordinary differential equations. NeurIPS. [Google Scholar]
  • 219. Baytas IM, Xiao C, Zhang X, Wang F, Jain AK, Zhou J. 2017. Patient subtyping via time-aware LSTM networks. Proceedings of the 23rd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. ACM, New York, NY, USA [Google Scholar]
  • 220. Rubanova Y, Chen RTQ, Duvenaud D. 2019. Latent ODEs for irregularly-sampled time series. arXiv. doi: 10.48550/arXiv.1907.03907 [DOI]
  • 221. Gu A, Dao T. 2023. Mamba: linear-time sequence modeling with selective state spaces. arXiv. doi: 10.48550/arXiv.2312.00752 [DOI]
  • 222. Mao A, Mohri M, Zhong Y. 2023. Cross-entropy loss functions: theoretical analysis and applications. arXiv. doi: 10.48550/arXiv.2304.07288 [DOI]
  • 223. Altmann A, Toloşi L, Sander O, Lengauer T. 2010. Permutation importance: a corrected feature importance measure. Bioinformatics 26:1340–1347. doi: 10.1093/bioinformatics/btq134 [DOI] [PubMed] [Google Scholar]
  • 224. Lundberg S, Lee S-I. 2017. A unified approach to interpreting model predictions. arXiv. doi: 10.48550/arXiv.1705.07874 [DOI]
  • 225. Arras L, Osman A, Samek W. 2022. CLEVR-XAI: a benchmark dataset for the ground truth evaluation of neural network explanations. Inf Fusion 81:14–40. doi: 10.1016/j.inffus.2021.11.008 [DOI] [Google Scholar]
  • 226. Elmarakeby HA, Hwang J, Arafeh R, Crowdis J, Gang S, Liu D, AlDubayan SH, Salari K, Kregel S, Richter C, Arnoff TE, et al. 2021. Biologically informed deep neural network for prostate cancer discovery. Nature 598:348–352. doi: 10.1038/s41586-021-03922-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 227. Esser-Skala W, Fortelny N. 2023. Reliable interpretability of biology-inspired deep neural networks. NPJ Syst Biol Appl 9:50. doi: 10.1038/s41540-023-00310-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 228. Wan C, Bachmann N, Mitov V, Blanquart F, Céspedes SP, Turk T, Neumann K, Beerenwinkel N, Bogojeska J, Fellay J, et al. , Swiss HIV Cohort Study . 2020. Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. Nat Commun 11:5542. doi: 10.1038/s41467-020-19198-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 229. De Clercq J, De Scheerder M-A, Mortier V, Verhofstede C, Vandecasteele SJ, Allard SD, Necsoi C, De Wit S, Gerlo S, Vandekerckhove L. 2023. Longitudinal patterns of inflammatory mediators after acute HIV infection correlate to intact and total reservoir. Front Immunol 14:1337316. doi: 10.3389/fimmu.2023.1337316 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 230. Salgado M, Gálvez C, Nijhuis M, Kwon M, Cardozo-Ojeda EF, Badiola J, Gorman MJ, Huyveneers LEP, Urrea V, Bandera A, et al. 2024. Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study. Lancet HIV 11:e389–e405. doi: 10.1016/S2352-3018(24)00090-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 231. Bahdanau D, Cho K, Bengio Y. 2014. Neural machine translation by jointly learning to align and translate. arXiv. doi: 10.48550/arXiv.1409.0473 [DOI]
  • 232. Poulton MM. 2001. Chapter 3 Multi-layer perceptrons and back-propagation learning, p 27–53. In Handbook of geophysical exploration: seismic exploration. Elsevier. [Google Scholar]
  • 233. Crooks AM, Bateson R, Cope AB, Dahl NP, Griggs MK, Kuruc JD, Gay CL, Eron JJ, Margolis DM, Bosch RJ, et al. 2015. Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies. J Infect Dis 212:1361–1365. doi: 10.1093/infdis/jiv218 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 234. Zantvoort K, Nacke B, Görlich D, Hornstein S, Jacobi C, Funk B. 2024. Estimation of minimal data sets sizes for machine learning predictions in digital mental health interventions. NPJ Digit Med 7:361. doi: 10.1038/s41746-024-01360-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 235. Wang T, Shao W, Huang Z, Tang H, Zhang J, Ding Z, Huang K. 2021. MOGONET integrates multi-omics data using graph convolutional networks allowing patient classification and biomarker identification. Nat Commun 12:3445. doi: 10.1038/s41467-021-23774-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 236. Laubenbacher R, Mehrad B, Shmulevich I, Trayanova N. 2024. Digital twins in medicine. Nat Comput Sci 4:184–191. doi: 10.1038/s43588-024-00607-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 237. De Domenico M, Allegri L, Caldarelli G, d’Andrea V, Di Camillo B, Rocha LM, Rozum J, Sbarbati R, Zambelli F. 2025. Challenges and opportunities for digital twins in precision medicine from a complex systems perspective. NPJ Digit Med 8:37. doi: 10.1038/s41746-024-01402-3 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES